

CHINA CDC WEEKLY



Vol. 4 No. 48 Dec. 2, 2022

中国疾病预防控制中心周报

**Get Informed.
Get Screened.
Get Vaccinated.**

**Cervical cancer can be prevented
and treated, if caught early.**

World Health
Organization
Get Informed. Get Vaccinated. Get Screened.

CERVICAL CANCER PREVENTION AND CONTROL**Foreword**

Accelerating Cervical Cancer Prevention and Control in China to Achieve Cervical Cancer Elimination Strategy Objectives 1067

Vital Surveillances

Trends in Incidence Rates, Mortality Rates, and Age-Period-Cohort Effects of Cervical Cancer — China, 2003–2017 1070

Preplanned Studies

Cervical Cancer Screening Coverage — China, 2018–2019 1077

Prevalence of High-Risk Human Papillomavirus in Cervical Intraepithelial Neoplasia in the Pre-Vaccine Era — China, 2017–2018 1083

Prevalence of High-Risk Human Papillomavirus by Subtypes Among Rural Women Aged 35–64 Years — Guangzhou City, Guangdong Province, China, 2019–2021 1088



ISSN 2096-7071



Editorial Board

Editor-in-Chief Hongbing Shen

Founding Editor George F. Gao

Deputy Editor-in-Chief Liming Li Gabriel M Leung Zijian Feng

Executive Editor Feng Tan

Members of the Editorial Board

Rui Chen	Wen Chen	Xi Chen (USA)	Zhuo Chen (USA)
Gangqiang Ding	Xiaoping Dong	Pei Gao	Mengjie Han
Yuantaao Hao	Na He	Yuping He	Guoqing Hu
Zhibin Hu	Yueqin Huang	Na Jia	Weihua Jia
Zhongwei Jia	Guangfu Jin	Xi Jin	Biao Kan
Haidong Kan	Ni Li	Qun Li	Ying Li
Zhenjun Li	Min Liu	Qiyong Liu	Xiangfeng Lu
Jun Lyu	Huilai Ma	Jiaqi Ma	Chen Mao
Xiaoping Miao	Ron Moolenaar (USA)	Daxin Ni	An Pan
Lance Rodewald (USA)	William W. Schluter (USA)	Yiming Shao	Xiaoming Shi
Yuelong Shu	RJ Simonds (USA)	Xuemei Su	Chengye Sun
Quanfu Sun	Xin Sun	Jinling Tang	Huaqing Wang
Hui Wang	Linhong Wang	Tong Wang	Guizhen Wu
Jing Wu	Xifeng Wu (USA)	Yongning Wu	Zunyou Wu
Min Xia	Ningshao Xia	Yankai Xia	Lin Xiao
Wenbo Xu	Hongyan Yao	Zundong Yin	Dianke Yu
Hongjie Yu	Shicheng Yu	Ben Zhang	Jun Zhang
Liubo Zhang	Wenhua Zhao	Yanlin Zhao	Xiaoying Zheng
Maigeng Zhou	Xiaonong Zhou	Guihua Zhuang	

Advisory Board

Director of the Advisory Board Jiang Lu

Vice-Director of the Advisory Board Yu Wang Jianjun Liu Jun Yan

Members of the Advisory Board

Chen Fu	Gauden Galea (Malta)	Dongfeng Gu	Qing Gu
Yan Guo	Ailan Li	Jiafa Liu	Peilong Liu
Yuanli Liu	Kai Lu	Roberta Ness (USA)	Guang Ning
Minghui Ren	Chen Wang	Hua Wang	Kean Wang
Xiaoqi Wang	Zijun Wang	Fan Wu	Xianping Wu
Jingjing Xi	Jianguo Xu	Gonghuan Yang	Tilahun Yilma (USA)
Guang Zeng	Xiaopeng Zeng	Yonghui Zhang	Bin Zou

Editorial Office

Directing Editor Feng Tan

Managing Editors Lijie Zhang

Senior Scientific Editors Ning Wang

Scientific Editors Weihong Chen

Meng Wang

Ying Zhang

Yu Chen

Ruotao Wang

Xudong Li

Zhihui Wang

Peter Hao (USA)

Shicheng Yu

Nankun Liu

Xi Xu

Qian Zhu

Liuying Tang

Qing Yue

Cover Image: adapted from the World Health Organization, <https://www.who.int/multi-media/details/get-informed.-get-screened.-get-vaccinated>.

This week's issue was organized by Guest Editor Linhong Wang.

Foreword

Accelerating Cervical Cancer Prevention and Control in China to Achieve Cervical Cancer Elimination Strategy Objectives

Linhong Wang^{1,2,#}

Cervical cancer is one of many types of cancers that severely threaten women's health. Each year, 604,000 new cases of cervical cancer appear with 342,000 related deaths globally. China represents about 18% of global incidences and 17% of global deaths (1). The China Cancer Registry's annual report determined that, in 2020, world-standardized incidence rate of cervical cancer was 11.35 per 100,000 women — accompanied by a mortality rate of 3.42 per 100,000 women in China; further, both have demonstrated upward trends (2). Thus, China faces serious challenges with cervical cancer prevention and control: creating a major public health problem that severely threatens women's health.

China has long paid great attention to the prevention and treatment of cervical cancer. In 2009, China initiated a screening program for cervical cancer and breast cancer for rural women as a National Major Public Health Service Project (3), leading to the improvement of cervical cancer screening coverage nationwide. Following this initiative, free screening was provided to rural women aged 35–64 years in the same project areas. Relevant agencies explored options around building screening service systems suitable for local healthcare operations and optimized the screening program's implementation plan, which gradually formed institutionalized and standardized operation mechanisms for regular cervical cancer screening services. In recent years, different local provinces and regions have also been actively exploring effective models for comprehensive prevention and treatment of cervical cancer. In many regions, cervical cancer screening has been launched as a local public welfare project, with the aim of building a full-chain, closed-loop management model for cervical cancer prevention and treatment. In addition, big data has been used to promote scientific, standardized, and precise prevention and treatment of cervical cancer. In 2019, the national cervical cancer screening program became a National Basic Public Health Service Project in order to further expand screening coverage of cervical cancer. The Healthy China Action Plan (2019–2030) further specified objectives and strategies for gradually improving screening coverage of cervical cancer, promoting Human Papillomavirus (HPV) vaccination, and improving the accessibility of HPV vaccines (4).

With advances in science and technology, and improved prevention and control measures, it has been proven that the incidence and mortality of cervical cancer can be greatly reduced (or even eliminated) through multi-pronged prevention measures. In November 2020, the World Health Organization (WHO) officially released the Global Strategy for Accelerating the Elimination of Cervical Cancer as a Public Health Problem, which depicted the grand vision of eliminating cervical cancer by the end of this century. The strategy proposed the goal of “90-70-90”, which stated that, by 2030, 90% of girls will have completed HPV vaccination by the age of 15; 70% of women will have been screened for high-precision tests by the age of 35–45; and 90% of women with cervical precancerous lesions and cervical cancer will have received treatment (5). China has actively responded to the WHO strategy and prioritized the prevention and control of cervical cancer. In the newly released China Women's Development Guidelines (2021–2030), China clearly identified objectives including raising women's awareness of cervical cancer prevention and treatment, continuously improving the prevention and treatment capacity for cervical cancer, and achieving 70% screening coverage of targeted female age groups (6). To effectively achieve these objectives, several strategies and measures were also recommended as follows. First, China must increase the dissemination of health knowledge among women and improve public awareness of core knowledge about cervical cancer prevention and treatment. Second, China needs to actively promote free HPV vaccination for school-aged girls in areas where conditions permit, while gradually increasing the HPV vaccination rate for girls aged 9–14 years, as well as promote pilots and accelerate public health campaign publicity. Third, China should continue to implement women's cervical cancer screening programs and comprehensively accelerate the improvement of cervical cancer screening rates among women. Fourth, China has to strengthen innovative applications of cervical cancer screening and diagnostic technologies, explore screening methods and strategies suitable for China, focus on improving the

screening and service capacities of local institutions, strengthen the building of information management systems and big data applications, and strengthen quality control, monitoring, and evaluation. Finally, China needs to improve the tracking and management of those with abnormal screening results, strengthen the connectivity between screening and follow-up diagnosis and treatment services, and promote early diagnosis and treatment (7).

Given the massive number of women in China, as well as regional imbalances of health resources, it has been found that the provision of basic services in cervical cancer (vaccination, screening, and treatment) is still lacking. HPV vaccination has begun only recently and faces a supply shortage due to insufficient domestic production capacity, while HPV vaccination rate in the targeted 9–14 age groups remains quite low. Women's awareness of cervical cancer screening as well as screening coverage rates are both low, and gaps exist in the provision of high-precision screening techniques and system management that ensures quality control of screening and follow-up treatment. China still faces many challenges in trying to meet the objectives of the cervical cancer elimination strategy. It is essential that cervical cancer elimination models are adjusted to suit China's needs and current circumstances, accommodating the different developmental phases of regions in particular, in order to help achieve China's goal of the elimination of cervical cancer.

This Weekly issue convened a special issue on cervical cancer prevention and control. The China Cancer Registry team was invited to analyze age-specific characteristics and trends, as well as the age-period-cohort (APC) effects of incidence and mortality of cervical cancer in China using their long-term data (8). Wang's team applied China's Chronic Disease and Nutrition Surveillance data to estimate the latest screening coverage rates of cervical cancer in China, demonstrating regional and provincial differences as well as the effects of age, education, occupation, income, and health insurance on screening service utilization (9). Bao et al. multicentric clinical study aimed to evaluate the effects of multiple screening strategies and the prevalence of human papillomavirus infection in women with precancerous lesions (10). The study provides ample evidence for the future implementation of HPV-based screening and vaccination strategies at the population level. Qiu's team analyzed the distribution of high-risk HPV subtype infections using local HPV screening data (11). Characterizing the epidemiological trends of HPV subtypes is beneficial to the identification and follow-up of high-risk populations as well as provides scientific support for precise prevention and control measures for cervical cancer.

These articles provide evidence from multiple aspects of surveillance and research on the prevention and control of cervical cancer in China, including the trends and characteristics of cervical cancer incidence and mortality across different time periods and different regions (urban and rural areas), the distribution of high-risk HPV subtype infections across populations of women, the association between different HPV infection patterns with high-grade cervical precancerous lesions before the advent of large-scale HPV vaccinations, and the phased effect and gap of current implementation of cervical cancer screenings in China. These data and research recommendations are extremely important for identifying target population groups for prevention and control measures, exploring suitable screening strategies, achieving precise prevention and control, and proposing future, multi-tier cervical cancer prevention and control models that suit regions in different developmental phases in China. This special issue calls for the joint efforts of all parties to continue to reduce the threats of cervical cancer to women's health and lives so that one day cervical cancer might be eliminated for good.

doi: 10.46234/ccdcw2022.215

Corresponding author: Linhong Wang, linhong@chinawch.org.cn.

¹ National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China; ² Women's Health Care Branch, Chinese Preventive Medicine Association, Beijing, China.

Submitted: November 02, 2022; Accepted: November 22, 2022

REFERENCES

1. World Health Organization. Global Cancer Observatory: Cancer Today. <https://gco.iarc.fr/today/home>. [2022-11-1].
2. He J, Wei WQ. China cancer registry annual report 2020. Beijing: People's Medical Publishing House. 2022. <https://book.kongfz.com/575075/5231142426/>. (In Chinese).
3. Women and Children's Health Division, Department of Health. Department of health and national women's federation notice of issuance of management plan of rural women's "two cancers" screening program. <http://www.nhc.gov.cn/fys/s3581/200906/cd3c33a7ad624a50b8100b262041dabe.shtml>. [2022-11-1]. (In Chinese).

4. Promotion Committee on Healthy China Initiative. Healthy China action plan (2019-2030). http://www.gov.cn/xinwen/2019-07/15/content_5409694.htm. [2022-11-1]. (In Chinese).
5. World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. <https://www.who.int/publications/item/9789240014107>. [2022-6-28].
6. The State Council. China women's development guidelines (2021-2030). http://www.gov.cn/zhengce/content/2021-09/27/content_5639412.htm. [2022-11-1]. (In Chinese).
7. Wang LH. Promoting women's life-cycle health and practicing high-quality development of whole-process services. *Chin J Women Child Health* 2021;12(5):1 - 4. <http://dx.doi.org/10.19757/j.cnki.issn1674-7763.2021.05.001>. (In Chinese).
8. Sun KX, Zheng RS, Lei L, Zhang SW, Zeng HM, Wang SM, et al. Trends in incidence rates, mortality rates, and age-period-cohort effects of cervical cancer — China, 2003–2017. *China CDC Wkly* 2022;4(48):1070 - 6. <http://dx.doi.org/10.46234/ccdcw2022.216>.
9. Zhang M, Zhong YJ, Wang LM, Bao HL, Huang ZJ, Zhao ZP, et al. Cervical cancer screening coverage—China, 2018–2019. *China CDC Wkly* 2022;4(48):1077 - 82. <http://dx.doi.org/10.46234/ccdcw2022.217>.
10. Bao HL, Chen WH, Zhang XS, Bi H, Zhao Y, Cong S, et al. Prevalence of high-risk human papillomavirus in cervical intraepithelial neoplasia in the pre-vaccine era — China, 2017–2018. *China CDC Wkly* 2022;4(48):1083 - 7. <http://dx.doi.org/10.46234/ccdcw2022.218>.
11. Shao DT, Xia XY, Liu HH, Huang MX, Yu J, He JR, et al. Prevalence of high-risk human papillomavirus by subtypes among rural women aged 35–64 years — Guangzhou City, Guangdong Province, China, 2019–2021. *China CDC Wkly* 2022;4(48):1088 - 91. <http://dx.doi.org/10.46234/ccdcw2022.219>.



Linhong Wang

Professor and Chief Expert of the National Center for Chronic and Noncommunicable Disease Control and Prevention, China CDC
Women's Health Care Branch, Chinese Preventive Medicine Association

Vital Surveillances

Trends in Incidence Rates, Mortality Rates, and Age-Period-Cohort Effects of Cervical Cancer — China, 2003–2017

Kexin Sun¹; Rongshou Zheng¹; Lin Lei²; Siwei Zhang¹; Hongmei Zeng¹; Shaoming Wang¹; Li Li¹; Ru Chen¹; Bingfeng Han^{1,2,3}; Ji Peng²; Wenqiang Wei^{1,*}; Jie He^{3,#}

ABSTRACT

Introduction: This study reported the trends and analyzed the age-period-cohort effects on the incidence and mortality rates of cervical cancer in China.

Methods: The age-standardized incidence rate (ASIR) and mortality rate (ASMR) by Segi's world standard population were calculated using qualified consecutive data from 22 cancer registries from 2003 to 2017 in China. We performed joinpoint analysis to describe the trends and age-period-cohort analysis to estimate the independent effects of age, period and cohort on trends in incidence and mortality rates of cervical cancer.

Results: The ASIR and ASMR for cervical cancer in females over 20 years old increased during 2003–2017. For females <50 years, a decreasing trend in ASIR and a stable trend in ASMR were observed in urban areas after 2009. But the ASIR and ASMR kept increasing in rural areas during the whole period. For females >50 years, the ASIR and ASMR increased both in urban and rural areas. Age-period-cohort analysis showed increasing period effects on cervical cancer incidence and mortality during the whole period. The cohort effects exhibited a downward-upward-downward pattern for the incidence (1918–1938, 1938–1963, 1963–1993) and mortality rates (1918–1943, 1943–1963, 1963–1993) in urban areas, a fluctuating pattern for incidence rate and a continuing downward pattern for mortality rate (1918–1993) in rural areas.

Conclusions: The increases in cervical cancer incidence and mortality rates can be mostly explained by period effects. We observed decreases in risk for cervical cancer incidence and mortality in young female generations, which were more obvious in urban areas.

Cervical cancer is a major public health problem

among women in China. China is one of the few countries experiencing an increase in cervical cancer incidence (1). Middle-aged females with large social and family responsibilities are at high risk of cervical cancer incidence, which results in poor health outcomes and an increased financial burden. Therefore, there has been much concern about the changing trend in age distribution of cervical cancer.

In recent years, the Chinese government has devoted resources to preventing and treating cervical cancer in rural areas (2). Currently, there is a gap in the literature examining incidence and mortality of cervical cancer in China (3). Hence, we aimed to describe the trends in incidence and mortality rates of cervical cancer from 2003 to 2017 and to identify risk factors for cervical cancer by geography. Our study can provide references for effectiveness evaluation of existing anticancer strategies and for future policy planning in China.

METHODS

Cancer Registry Data

We extracted and pooled cervical cancer datasets (codes: C53, International Statistical Classification of Diseases and Related Health Problems 10th Revision) of 22 population-based cancer registries (11 in urban areas and 11 in rural areas) from 2003 to 2017 in China. A total of 41,326 cervical cancer cases and 10,863 cancer deaths from a population of 329,750,392 person-years (35,420 cases and 8,899 deaths from 274,073,539 person-years in urban areas and 5,906 cases and 1,964 deaths from 55,676,853 person-years in rural areas).

We excluded data from females over 20 years old since the number of cases and deaths of females in this population was less than 5 in each age group ($n < 5$). We classified districts as urban areas and counties/county-level cities as rural areas. The incidence and mortality rates were calculated using 5-year age grouping (20–24, 25–29, ..., 80–, ≥ 85), by 5-

year period (2003–2007, 2008–2012, 2013–2017) and by geography (urban and rural areas).

Statistical Analysis

The age-standardized incidence rate (ASIR) and mortality rate (ASMR) were calculated using Segi's world standard population (4). We used Joinpoint regression analyses for trend analysis and reported the annual percent changes (APC), and average annual percent change (AAPC). Age-period-cohort effects were analyzed using the intrinsic estimator method and risk ratios were reported (5). Statistical analyses were performed using Stata (version 13.0, Stata Corporation, College Station, Texas, USA) and Joinpoint software (version 4.6.0.0 Applications Branch, National Cancer Institute, Bethesda, USA).

RESULTS

Trends in Incidence Rate

Supplementary Table S1 (available in <http://weekly.chinacdc.cn>) presents the incidence rates of cervical cancer. Overall, the ASIR for cervical cancer in females over 20 years old increased from 6.66/100,000 in 2003 to 16.30/100,000 in 2017. A clear upward trend was observed during 2003–2007, but this trend dampened during 2007–2017. In urban areas, the ASIR increased from 6.91/100,000 in 2003 to 16.15/100,000 in 2017. ASIR increased significantly during 2003–2009, and then leveled off. In rural areas, the ASIR increased from 5.72/100,000 in 2003 to 17.07/100,000 in 2017. The ASIR increased during 2003–2007, however, this upward trend slowed down during 2007–2017 (Figures 1A, 1B, 1C). The corresponding APCs and AAPCs for incidence rates were provided in Supplementary Table S2 (available in <http://weekly.chinacdc.cn>).

In urban areas, the ASIR in females aged 20–34 years decreased significantly from 2003–2017. The ASIR in females aged 35–49 years varied, increasing from 2003–2009, then decreasing from 2009–2017. The ASIR in females aged 50–64 years increased significantly during 2003–2006, however, this upward trend slowed down afterwards. The ASIR in females over 65 years increased during 2003–2017 (Figure 1B).

In rural areas, the ASIR in females aged 20–34 years and 50–64 years increased significantly during 2003–2017. The ASIR in females aged 35–49 years increased during 2003–2017. The ASIR in females over 65 years was stable during 2003–2010 but

increased rapidly afterward (Figure 1C).

Trends in Mortality Rate

Supplementary Table S3 (available in <http://weekly.chinacdc.cn>) presents the mortality rates of cervical cancer. In all areas, the ASMR increased from 2.07/100,000 in 2003 to 4.16/100,000 in 2017. In urban areas, it increased from 1.86/100,000 in 2003 to 3.91/100,000 in 2017. In rural areas, it increased from 3.12/100,000 in 2003 to 5.56/100,000 in 2017. The ASMRs all followed continuously increasing trends (Figures 1D, 1E, and 1F). The corresponding APCs and AAPCs for mortality rates were provided in Supplementary Table S4 (available in <http://weekly.chinacdc.cn>).

In urban areas, the ASMR in females aged 20–34 years stayed stable. The ASMR in females aged 35–49 years increased during 2003–2007 and then leveled off. The ASMR in females aged 50–64 years and over 65 years increased during the whole period of 2003–2017 (Figure 1E).

In rural areas, the increasing trend of ASMR in females aged 20–34 years was not significant. The ASMR in females aged 35–49 years increased during 2003–2017. The ASMR in females aged 50–64 years stayed stable. The ASMR in females over 65 years fluctuated during 2003–2009 and then increased during 2009–2017 (Figure 1F).

Trends in Age Distribution of Cervical Cancer Incidence

In urban areas, the peak age group for the incidence rate rose by one age group each 5-year period, from 40–44 years during 2003–2007 to 45–49 years during 2008–2012, and to 50–54 years during 2013–2017. Compared to period 2008–2012, the age-specific rates were lower in age groups <45 in period 2013–2017. The trends in all areas were similar to those in urban areas (Figure 2B).

In rural areas, the age group with the highest incidence rate was 55–59 years during 2003–2007. It decreased to 45–49 age group during 2008–2012, and then rose to 50–54 age group during 2013–2017. The age-specific incidences in most age groups increased with period (Figure 2C).

The incidence rates increased for cohorts between 1928 and 1978 (25–79 years) in urban areas and cohorts between 1918 and 1978 (>25 years) in rural areas (Figures 3A, 3B).

Trends in Age Distribution of Cervical




FIGURE 1. The trends of incidence and mortality rates of cervical cancer by age group and area, from 2003 to 2017. (A) Incidence rates in all areas, (B) Incidence rates in urban areas, (C) Incidence rates in rural areas, (D) Mortality rates in all areas, (E) Mortality rates in urban areas, (F) Mortality rates in rural areas.

Cancer Mortality

In urban areas, the age-specific mortality rate peaked at 45–49 years during 2003–2012 and at 50–54 years during 2013–2017. From the 60–64 year age group, mortality rates increased continuously with age. The trends in all areas were similar to those in urban areas

(Figure 2E).

In rural areas, the mortality rate increased with age all along, and no peaks were found in young age groups (Figure 2F).

The mortality rates of cervical cancer increased for younger cohorts between 1943 and 1978 but




FIGURE 2. The age-specific incidence and mortality rates of cervical cancer, by time period and area. (A) Incident rates in all areas. (B) Incident rates in urban areas. (C) Incident rates in rural areas. (D) Mortality rates in all areas. (E) Mortality rates in urban areas. (F) Mortality rates in rural areas.

Note: Each line represents the connection of age-specific rates for a 5-year period.

fluctuated in elder cohorts between 1918 and 1938 in both urban and rural areas (Figures 3C, 3D).

Results of Age-period-cohort Models

The age effect for cervical cancer incidence rates rose significantly from age groups 20–24 and peaked in the age groups of 45–49 (urban) and 50–54 (rural). It

began to decrease slowly afterward but rose again in the age group of 70–74. The age effect dropped rapidly in subsequent age groups. The age effect on mortality rates increased with age all through in urban areas but fluctuated in elder age groups in rural areas (Figure 4).

The period effect for the incidence and mortality rates of cervical cancer increased during 2003 to 2017




FIGURE 3. The birth cohort-specific incidence and mortality rates of cervical cancer, by area. (A) Incident rates in urban areas. (B) Incident rates in rural areas. (C) Mortality rates in urban areas. (D) Mortality rates in rural areas. Note: Results are not shown in age group 20–24 if the age-specific rate is 0. Each line represents the connection of cohort-specific rates for a 5-year age group.

in urban and rural areas (Figure 4).

For cohort effects in urban areas, the risk ratios of incidence and mortality rates decreased in birth cohorts 1918–1938 and 1918–1943, respectively. Then the risk ratios increased in birth cohorts 1938–1963 and 1943–1963, and decreased after 1963. In rural areas, the risk ratios of incidence rate decreased in birth cohort 1918–1943 and then fluctuated after that. The risk ratios of mortality rate decreased among all cohorts from 1918 to 1993 (Figure 4). The age-period-cohort estimates were provided in Supplementary Table S5–S6 (available in <http://weekly.chinacdc.cn>).

DISCUSSION

Shift in trends. Wang et al. (6) showed that the incident rates of cervical cancer were highest in younger populations in Italy and Korea. Similar trends were also observed in China whereby Wei et al. (7) found that the mortality rate of cervical cancer increased in young females aged 25–54 from 1987 to 2015 in urban China, which was different from the

results in our study. Li et al. (3) used cancer registry data and reported that the risk for younger females was rising in China. In this study, we updated the same cancer registry data for 3 years and found contrasting trends in incidence/mortality rates in younger females (<50) in recent 8 years, which were more significant in urban areas than in rural areas. This evidence indicated that the increasing trend in cervical cancer disease burden in younger females was being arrested in urban areas.

Age effect. We observed that the risk for cervical cancer incidence plateaued at age 40–74 in China, which was also observed in India (8) and Russia (9), indicating that the age span of targeted population for cervical cancer screening programs can be larger.

Period effect. The increased trends in cervical cancer incidence and mortality rates can be explained by period effects, which are caused by factors that can influence all age groups during a particular period of time. Considering that the National Cervical Cancer Screening Program in Rural Areas (NCCSPRA) was launched in 2009 for females aged 35–59, the effect of




FIGURE 4. The result of age-period-cohort analysis of incidence and mortality rates of cervical cancer, by area. (A) Incident rates in urban areas; (B) Incident rates in rural areas; (C) Mortality rates in urban areas; (D) Mortality rates in rural areas. Notes: Purple solid and dash lines represent the age effect and 95% confidence interval. Orange solid and dash lines represent the period effect and 95% confidence interval. Yellow solid and dash lines represent the cohort effect and 95% confidence interval.

this screening program may have resulted in the cohorts rather than the periods in China. Guo et al. (10) also reported similar period effects on cervical cancer mortality. The possible explanation might also be the cumulative exposure to risk factors during the industrialization and urbanization processes, the improvement of health service capacity and the increasing demand for cancer treatment. Surveillance data indicated that the cancer incidence and mortality rates are still on the rise and the turning point is not yet in sight in China (11). Without harsher and more extensive intervention measures, the period effect is expected to keep rising in the near future (12).

Cohort effect. Cohort effect explains the influence of unique risk factors for different birth cohorts. In urban areas, risk ratios increased among females born in 1938–1963, which was echoed in Guo’s research (10). Possible explanations include an increase in HPV infection and smoking rate and changing sexual behaviors in 1938–1963 cohorts (13). The risk ratios decreased among females born after 1963, which might be explained by the cancer intervention strategies implemented in recent years, including health education, the promotion of women’s health care and the implementation of extensive cervical cancer screening programs after 2009. In rural areas, we

observed no upward trends in cohort effects on incidence rate and decreased cohort effects on mortality rates, indicating that the cervical cancer intervention strategies in these areas have achieved promising effects. Increasing cohort effects were found in young generations in the Republic of Korea (14), Japan (15) and Russia (9) but were not observed in the present study. Considering that similar risk factors may also exist in China, corresponding public health measures for young generations should be implemented in advance.

In conclusion, the disease burden of cervical cancer in China is still on the rise, but the upward trend in young generations in urban areas is starting to slow down or even reverse. The decrease of cohort effects may reflect the effect of cervical cancer prevention and control strategies in China in recent years, which mainly affected females born after 1963 in urban areas and all females in rural areas. More comprehensive interventions for general female population with strengthened measures for young generations should be implemented in China.

Acknowledgments: Staffs of 22 population-based cancer registries for the effort they put in data collection, quality control and database creation, including Beijing Municipality; Cixian County in

Hebei Province; Dalian and Anshan cities in Liaoning Province; Nangang District in Heilongjiang Province; Shanghai Municipality; Qidong City, Huai'an District, and Yangzhong City in Jiangsu Province; Hangzhou City, Jiaxing City, Jiashan County, and Haining City in Zhejiang Province; Changle District in Fujian Province; Linqu County and Feicheng City in Shandong Province; Linzhou City in Henan Province; Wuhan City in Hubei Province; Guangzhou, Sihui, and Zhongshan cities in Guangdong Province; and Yanting County in Sichuan Province.

Conflicts of interest: No conflicts of interest.

Funding: Supported by CAMS Innovation Fund for Medical Sciences (2021-I2M-1-011) and Sanming Project of Medicine in Shenzhen (No.SZSM 20191015).

doi: 10.46234/ccdcw2022.216

* Corresponding authors: Wenqiang Wei, weiwq@cicams.ac.cn; Jie He, prof.hejie@263.net.

¹ National Central Cancer Registry, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Municipality, China; ² Shenzhen Center for Chronic Disease Control, Guangzhou City, Guangdong Province, China; ³ Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Municipality, China.

Submitted: October 26, 2022; Accepted: November 29, 2022

REFERENCES

1. He WQ, Li CX. Recent global burden of cervical cancer incidence and mortality, predictors, and temporal trends. *Gynecol Oncol* 2021;163(3):583 – 92. <http://dx.doi.org/10.1016/j.ygyno.2021.10.075>.
2. Zhao FH, Qiao YL. Cervical cancer prevention in China: a key to cancer control. *Lancet* 2019;393(10175):969 – 70. [http://dx.doi.org/10.1016/s0140-6736\(18\)32849-6](http://dx.doi.org/10.1016/s0140-6736(18)32849-6).
3. Li XT, Zheng RS, Li XM, Shan HB, Wu Q, Wang Y, et al. Trends of incidence rate and age at diagnosis for cervical cancer in China, from 2000 to 2014. *Chin J Cancer Res* 2017;29(6):477 – 86. <http://dx.doi.org/10.21147/j.issn.1000-9604.2017.06.02>.
4. Segi M. Cancer mortality for selected sites in 24 countries (1950-1957). Sendai: Department of Public Health. 1960. <https://discover.libraryhub.jisc.ac.uk/search?ti=Cancer%20Mortality%20for%20Selected%20Sites%20In%2024%20Countries&trn=3>.
5. Yang Y, Schulhofer-Wohl S, Fu WJ, Land KC. The intrinsic estimator for age-period-cohort analysis: what it is and how to use it. *Am J Sociol* 2008;113(6):1697 – 736. <http://dx.doi.org/10.1086/587154>.
6. Wang JY, Bai ZQ, Gao XD, Zhang NP, Wang ZK. The effects of age, period, and cohort on the mortality of cervical cancer in three high-income countries: Canada, Korea, and Italy. *Biomed Res Int* 2021;2021:8829122. <http://dx.doi.org/10.1155/2021/8829122>.
7. Wei M, Zhou W, Bi YY, Wang H, Liu Y, Zhang ZJ. Rising mortality rate of cervical cancer in younger women in urban China. *J Gen Intern Med* 2019;34(2):281 – 4. <http://dx.doi.org/10.1007/s11606-018-4732-z>.
8. Sathishkumar K, Vinodh N, Badwe RA, Deo SVS, Manoharan N, Malik R, et al. Trends in breast and cervical cancer in India under national cancer registry programme: an age-period-cohort analysis. *Cancer Epidemiol* 2021;74:101982. <http://dx.doi.org/10.1016/j.canep.2021.101982>.
9. Barchuk A, Bepalov A, Huhtala H, Chimed T, Laricheva I, Belyaev A, et al. Breast and cervical cancer incidence and mortality trends in Russia 1980-2013. *Cancer Epidemiol* 2018;55:73 – 80. <http://dx.doi.org/10.1016/j.canep.2018.05.008>.
10. Guo MH, Xu J, Du JY. Trends in cervical cancer mortality in China from 1989 to 2018: an age-period-cohort study and Joinpoint analysis. *BMC Public Health* 2021;21(1):1329. <http://dx.doi.org/10.1186/s12889-021-11401-8>.
11. Zheng RS, Zhang SW, Zeng HM, Wang SM, Sun KX, Chen R, et al. Cancer incidence and mortality in China, 2016. *J Natl Cancer Center* 2022;2(1):1 – 9. <http://dx.doi.org/10.1016/j.jncc.2022.02.002>.
12. Xia CF, Hu SY, Xu XQ, Zhao XL, Qiao YL, Broutet N, et al. Projections up to 2100 and a budget optimisation strategy towards cervical cancer elimination in China: a modelling study. *Lancet Public Health* 2019;4(9):e462 – 72. [http://dx.doi.org/10.1016/s2468-2667\(19\)30162-8](http://dx.doi.org/10.1016/s2468-2667(19)30162-8).
13. Ku Y, Li PY, Luo GF, Liu D, Zou HC. Cancer attributable to human papillomavirus infection in China: burden and trends. *Cancer* 2020;126(16):3719 – 32. <http://dx.doi.org/10.1002/cncr.32986>.
14. Moon EK, Oh CM, Won YJ, Lee JK, Jung KW, Cho H, et al. Trends and age-period-cohort effects on the incidence and mortality rate of cervical cancer in Korea. *Cancer Res Treat* 2017;49(2):526 – 33. <http://dx.doi.org/10.4143/crt.2016.316>.
15. Utada M, Chernyavskiy P, Lee WJ, Franceschi S, Sauvaget C, de Gonzalez AB, et al. Increasing risk of uterine cervical cancer among young Japanese women: comparison of incidence trends in Japan, South Korea and Japanese-Americans between 1985 and 2012. *Int J Cancer* 2019;144(9):2144 – 52. <http://dx.doi.org/10.1002/ijc.32014>.

SUPPLEMENTARY MATERIAL

SUPPLEMENTARY TABLE S1. The cervical cancer incidence in China by age group and area, 2003–2017.

Area	Year	20–34 years			35–49 years			50–64 years			>65 years			All >20 years			
		No.	CR	ASIR	No.	CR	ASIR	No.	CR	ASIR	No.	CR	ASIR	No.	CR	ASIR	
All	2003	135	3.02	2.66	539	10.99	10.95	204	7.00	6.83	183	8.25	7.86	1,061	7.32	6.66	
	2004	221	4.51	3.95	805	14.76	14.71	349	10.68	10.29	244	9.89	9.34	1,619	10.06	9.18	
	2005	195	3.88	3.64	926	16.98	16.94	401	11.26	11.07	263	10.18	10.19	1,785	10.74	10.01	
	2006	210	4.04	3.75	1,049	18.68	18.65	531	14.33	14.03	263	10.12	10.00	2,053	12.00	11.18	
	2007	240	4.59	4.29	1,199	21.30	21.26	617	15.48	14.90	282	10.51	10.29	2,338	13.34	12.38	
	2008	205	3.82	3.65	1,260	23.00	22.98	740	16.99	16.54	303	10.69	10.75	2,508	13.91	13.07	
	2009	234	4.33	4.24	1,452	26.44	26.26	887	19.20	18.69	302	10.44	10.44	2,875	15.61	14.70	
	2010	210	3.96	3.83	1,376	25.20	24.87	972	20.18	19.89	313	10.56	10.82	2,871	15.48	14.44	
	2011	192	3.71	3.44	1,413	25.83	25.22	1,055	20.84	20.59	372	12.00	13.03	3,032	16.13	14.81	
	2012	218	4.21	3.75	1,500	27.66	26.99	1,178	22.69	22.75	377	11.74	12.54	3,273	17.22	15.86	
	2013	166	3.21	2.70	1,403	26.52	25.94	1,397	25.68	25.90	455	13.72	14.50	3,421	17.80	16.07	
	2014	203	3.87	3.26	1,318	25.32	24.91	1,450	25.97	26.11	482	13.88	15.02	3,453	17.70	16.08	
	2015	196	3.85	3.10	1,223	23.58	23.25	1,586	27.31	27.46	514	14.09	15.45	3,519	17.84	15.86	
	2016	248	5.03	3.94	1,204	23.00	22.83	1,747	30.21	30.59	561	14.63	15.80	3,760	19.00	16.76	
	2017	179	3.73	2.83	1,241	23.09	22.92	1,670	28.87	29.42	645	16.27	17.24	3,735	18.75	16.30	
	Urban	2003	123	3.42	3.07	484	11.99	11.93	156	6.44	6.27	144	7.69	7.28	907	7.60	6.91
		2004	209	5.17	4.65	749	16.38	16.32	284	10.32	9.92	198	9.37	8.89	1,440	10.68	9.79
2005		179	4.30	4.10	844	18.48	18.47	335	11.05	10.83	223	10.03	10.02	1,581	11.30	10.56	
2006		189	4.36	4.11	950	20.11	20.05	444	14.00	13.72	232	10.37	10.30	1,815	12.55	11.69	
2007		208	4.75	4.57	1,047	22.13	22.07	527	15.37	14.68	242	10.41	10.09	2,024	13.62	12.65	
2008		188	4.15	4.06	1,087	23.72	23.69	649	17.35	16.84	260	10.62	10.76	2,184	14.27	13.50	
2009		210	4.62	4.59	1,280	27.90	27.67	738	18.66	18.07	261	10.48	10.43	2,489	15.98	15.12	
2010		179	4.01	3.89	1,206	26.68	26.32	841	20.60	20.09	275	10.81	11.25	2,501	16.02	14.99	
2011		166	3.83	3.49	1,246	27.54	26.92	930	21.54	21.27	323	12.06	13.21	2,665	16.81	15.50	
2012		185	4.30	3.74	1,278	28.70	28.03	1,028	23.28	23.29	322	11.66	12.52	2,813	17.65	16.29	
2013		139	3.25	2.67	1,202	27.69	27.16	1,200	25.84	26.11	384	13.46	14.21	2,925	18.16	16.44	
2014		164	3.76	3.13	1,099	25.82	25.47	1,234	25.89	26.08	397	13.29	14.42	2,894	17.68	16.12	
2015		167	3.95	3.14	996	23.33	23.10	1,342	27.06	27.21	436	13.92	15.29	2,941	17.72	15.76	
2016		199	4.87	3.71	987	22.77	22.69	1,449	29.40	29.83	467	14.15	15.52	3,102	18.63	16.44	
2017		142	3.58	2.67	1,019	22.83	22.81	1,418	28.80	29.44	539	15.76	16.67	3,118	18.58	16.15	
Rural		2003	12	1.38	1.12	55	6.33	6.43	48	9.82	9.64	39	11.29	11.03	154	5.99	5.72
		2004	12	1.39	1.03	56	6.36	6.52	65	12.58	12.25	46	12.99	12.12	179	6.85	6.40
	2005	16	1.87	1.72	82	9.24	9.36	66	12.42	12.43	40	11.11	11.26	204	7.74	7.44	
	2006	21	2.44	2.17	99	11.11	11.19	87	16.28	15.95	31	8.58	8.17	238	8.99	8.56	
	2007	32	3.77	3.26	152	16.93	17.18	90	16.14	16.14	40	11.21	11.52	314	11.80	11.19	
	2008	17	2.04	1.80	173	19.34	19.38	91	14.76	14.63	43	11.12	10.86	324	11.87	10.91	
	2009	24	2.76	2.53	172	19.04	18.96	149	22.35	22.12	41	10.16	10.55	386	13.58	12.64	
	2010	31	3.68	3.48	170	18.11	17.94	131	17.89	18.14	38	9.09	8.63	370	12.63	11.59	
	2011	26	3.09	3.12	167	17.64	17.15	125	16.79	16.47	49	11.64	11.98	367	12.43	11.26	
	2012	33	3.76	3.79	222	22.91	22.18	150	19.31	19.60	55	12.24	12.82	460	14.97	13.79	
	2013	27	3.01	2.93	201	21.16	20.34	197	24.71	24.67	71	15.30	16.18	496	15.95	14.41	
	2014	39	4.42	4.21	219	23.09	22.46	216	26.48	26.40	85	17.46	18.42	559	17.84	16.15	
	2015	29	3.39	2.96	227	24.73	23.94	244	28.78	28.84	78	15.13	16.22	578	18.43	16.41	
	2016	49	5.78	5.10	217	24.11	23.54	298	34.88	34.85	94	17.58	17.70	658	20.97	18.55	
	2017	37	4.47	3.76	222	24.36	23.16	252	29.28	29.34	106	19.53	20.44	617	19.64	17.07	

Note: Urban: districts are defined as urban areas. Rural: Counties or county-level cities are defined as rural areas. Abbreviation: CR=crude rate; ASIR=age-standardized incidence rate.

SUPPLEMENTARY TABLE S2. Trends for age-standardized incidence rates of cervical cancer for any time segments identified in joinpoint analysis by age group and area, 2003 to 2017.

Age, years	Area	Trend1		Trend2		AAPC	
		Years	APC (95% CI)	Years	APC (95% CI)	2003–2017	2013–2017
20–34	All	2003–2017	-0.9 (-2.9, 1.1)	-	-	-0.9 (-2.9, 1.1)	-0.9 (-2.9, 1.1)
	Urban	2003–2017	-2.4* (-4.3, -0.4)	-	-	-2.4* (-4.3, -0.4)	-2.4* (-4.3, -0.4)
	Rural	2003–2017	9.3* (5.7, 13.0)	-	-	9.3* (5.7, 13.0)	9.3* (5.7, 13.0)
35–49	All	2003–2009	14.1* (10.8, 17.6)	2009–2017	-2.0* (-3.9, -0.1)	4.6* (3.1, 6.2)	-2.0* (-3.9, -0.1)
	Urban	2003–2009	13.4* (9.5, 17.4)	2009–2017	-2.7* (-4.8, -0.5)	3.9* (2.1, 5.7)	-2.7* (-4.8, -0.5)
	Rural	2003–2008	25.6* (17.9, 33.8)	2008–2017	2.8* (0.2, 5.5)	10.5* (7.8, 13.2)	2.8* (0.2, 5.5)
50–64	All	2003–2006	25.9* (14.3, 38.6)	2006–2017	7.5* (6.1, 8.9)	11.2* (8.9, 13.4)	7.5* (6.1, 8.9)
	Urban	2003–2006	29.0* (16.2, 43.3)	2006–2017	7.5* (6.0, 9.0)	11.8* (9.3, 14.3)	7.5* (6.0, 9.0)
	Rural	2003–2017	8.1* (6.4, 9.9)	-	-	8.1* (6.4, 9.9)	8.1* (6.4, 9.9)
>65	All	2003–2017	5.1* (4.3, 5.9)	-	-	5.1* (4.3, 5.9)	5.1* (4.3, 5.9)
	Urban	2003–2017	5.2* (4.4, 6.0)	-	-	5.2* (4.4, 6.0)	5.2* (4.4, 6.0)
	Rural	2003–2010	-1.1 (-5.9, 3.8)	2010–2017	11.1* (5.8, 16.7)	4.8* (1.7, 8.1)	11.1* (5.8, 16.7)
All >20	All	2003–2007	16.6* (11.0, 22.6)	2007–2017	2.6* (1.3, 3.8)	6.4* (4.9, 8.0)	2.6* (1.3, 3.8)
	Urban	2003–2009	11.8* (8.1, 15.5)	2009–2017	0.6 (-1.5, 2.8)	5.3* (3.5, 7.0)	0.6 (-1.5, 2.8)
	Rural	2003–2007	16.9* (9.5, 24.8)	2007–2017	5.7* (4.0, 7.4)	8.8* (6.7, 10.9)	5.7* (4.0, 7.4)

Note: "-" denotes no data.

Abbreviation: APC=annual percent change; AAPC=average annual percent change; CI=confidence interval.

*APC or AAPC with statistically significant trends, $P < 0.05$.

SUPPLEMENTARY TABLE S3. The cervical cancer mortality in China by age group and area, 2003–2017.

Area	Year	20–34			35–49			50–64			>65			All >20		
		No	CR	ASWR	No	CR	ASWR	No	CR	ASWR	No	CR	ASWR	No	CR	ASWR
All	2003	14	0.31	0.27	95	1.94	1.92	86	2.95	3.00	155	6.99	6.32	350	2.41	2.07
	2004	26	0.53	0.50	125	2.29	2.28	95	2.91	2.97	183	7.42	6.82	429	2.67	2.31
	2005	9	0.18	0.16	135	2.48	2.44	101	2.83	2.85	217	8.40	7.61	462	2.78	2.30
	2006	19	0.37	0.33	165	2.94	2.94	133	3.59	3.59	202	7.77	7.04	519	3.03	2.60
	2007	22	0.42	0.41	183	3.25	3.27	138	3.46	3.42	173	6.45	5.74	516	2.94	2.54
	2008	19	0.35	0.34	179	3.27	3.24	179	4.11	4.10	225	7.94	6.72	602	3.34	2.77
	2009	21	0.39	0.38	187	3.41	3.34	227	4.91	4.94	253	8.74	7.40	688	3.74	3.08
	2010	29	0.55	0.53	223	4.08	3.98	230	4.78	4.79	264	8.91	7.80	746	4.02	3.34
	2011	21	0.41	0.38	193	3.53	3.42	264	5.21	5.14	258	8.33	6.89	736	3.91	3.08
	2012	24	0.46	0.44	242	4.46	4.26	273	5.26	5.27	262	8.16	6.89	801	4.21	3.38
	2013	19	0.37	0.31	231	4.37	4.24	304	5.59	5.57	334	10.07	9.01	888	4.62	3.64
	2014	18	0.34	0.28	199	3.82	3.75	386	6.91	6.93	328	9.44	8.06	931	4.77	3.67
	2015	17	0.33	0.27	187	3.61	3.53	416	7.16	7.21	375	10.28	9.04	995	5.04	3.77
	2016	25	0.51	0.40	216	4.13	4.04	483	8.35	8.34	364	9.49	8.93	1,088	5.50	4.21
2017	25	0.52	0.38	229	4.26	4.19	444	7.68	7.73	410	10.34	9.35	1,108	5.56	4.16	
Urban	2003	11	0.31	0.27	75	1.86	1.84	59	2.43	2.41	122	6.51	5.87	267	2.24	1.86
	2004	24	0.59	0.56	112	2.45	2.44	67	2.43	2.47	145	6.86	6.17	348	2.58	2.19
	2005	8	0.19	0.17	108	2.37	2.32	76	2.51	2.42	180	8.09	7.23	372	2.66	2.13
	2006	16	0.37	0.34	134	2.84	2.82	94	2.96	2.95	165	7.38	6.69	409	2.83	2.39
	2007	14	0.32	0.30	162	3.42	3.44	100	2.92	2.87	140	6.02	5.17	416	2.80	2.37
	2008	15	0.33	0.33	147	3.21	3.17	140	3.74	3.69	197	8.05	6.70	499	3.26	2.65
	2009	16	0.35	0.35	162	3.53	3.45	180	4.55	4.53	220	8.84	7.55	578	3.71	3.03
	2010	22	0.49	0.48	185	4.09	3.97	188	4.60	4.59	226	8.88	7.78	621	3.98	3.27
	2011	17	0.39	0.36	156	3.45	3.35	211	4.89	4.80	222	8.29	6.80	606	3.82	2.97
	2012	20	0.46	0.43	203	4.56	4.34	226	5.12	5.14	219	7.93	6.47	668	4.19	3.33
	2013	14	0.33	0.26	191	4.40	4.27	252	5.43	5.41	277	9.71	8.59	734	4.56	3.55
	2014	14	0.32	0.25	173	4.06	4.01	333	6.99	7.01	253	8.47	7.01	773	4.72	3.63
	2015	12	0.28	0.22	150	3.51	3.46	360	7.26	7.31	309	9.86	8.53	831	5.01	3.70
	2016	21	0.51	0.41	173	3.99	3.93	396	8.03	8.00	297	9.00	8.34	887	5.33	4.04
2017	20	0.50	0.35	178	3.99	3.95	362	7.35	7.42	327	9.56	8.45	887	5.29	3.91	
Rural	2003	3	0.35	0.29	20	2.30	2.33	27	5.52	5.95	33	9.55	8.81	83	3.23	3.12
	2004	2	0.23	0.26	13	1.48	1.51	28	5.42	5.60	38	10.73	10.78	81	3.10	3.02
	2005	1	0.12	0.08	27	3.04	3.12	25	4.70	5.13	37	10.28	9.83	90	3.41	3.23
	2006	3	0.35	0.36	31	3.48	3.51	39	7.30	7.38	37	10.24	9.28	110	4.15	3.87
	2007	8	0.94	1.03	21	2.34	2.40	38	6.82	6.76	33	9.25	9.21	100	3.76	3.64
	2008	4	0.48	0.46	32	3.58	3.60	39	6.33	6.45	28	7.24	6.72	103	3.77	3.43
	2009	5	0.58	0.50	25	2.77	2.76	47	7.05	7.15	33	8.17	6.61	110	3.87	3.33
	2010	7	0.83	0.76	38	4.05	4.01	42	5.73	5.73	38	9.09	8.07	125	4.27	3.66
	2011	4	0.48	0.48	37	3.91	3.79	53	7.12	6.99	36	8.55	7.57	130	4.40	3.71
	2012	4	0.46	0.45	39	4.02	3.85	47	6.05	5.99	43	9.57	9.11	133	4.33	3.68
	2013	5	0.56	0.54	40	4.21	4.12	52	6.52	6.48	57	12.28	11.43	154	4.95	4.17
	2014	4	0.45	0.45	26	2.74	2.61	53	6.50	6.53	75	15.41	14.24	158	5.04	4.02
	2015	5	0.59	0.51	37	4.03	3.78	56	6.61	6.63	66	12.80	11.97	164	5.23	4.15
	2016	4	0.47	0.39	43	4.78	4.63	87	10.18	10.17	67	12.53	12.30	201	6.41	5.17
2017	5	0.60	0.51	51	5.60	5.30	82	9.53	9.53	83	15.29	14.73	221	7.03	5.56	

Note: Urban: Districts are defined as urban areas. Rural: Counties or county-level cities are defined as rural areas.
Abbreviation: CR=crude rate; ASWR=age-standardized mortality rate.

SUPPLEMENTARY TABLE S4. Trends in age-standardized mortality rates of cervical cancer for any time segments identified in joinpoint analysis by age group and area, 2003–2017.

Age (years)	Area	Trend1		Trend2		AAPC	
		Year	APC (95% CI)	Year	APC (95% CI)	2003–2017	2013–2017
20–34	All	2003–2017	1.0 (–2.9, 5.0)	–	–	1.0 (–2.9, 5.0)	1.0 (–2.9, 5.0)
	Urban	2003–2017	0.0 (–4.0, 4.3)	–	–	0.0 (–4.0, 4.3)	0.0 (–4.0, 4.3)
	Rural	2003–2017	5.3 (–1.7, 12.9)	–	–	5.3 (–1.7, 12.9)	5.3 (–1.7, 12.9)
35–49	All	2003–2007	14.7* (5.7, 24.6)	2007–2017	2.2* (0.2, 4.3)	5.6* (3.1, 8.2)	2.2* (0.2, 4.3)
	Urban	2003–2007	15.7* (4.7, 27.9)	2007–2017	1.9 (–0.6, 4.4)	5.7* (2.6, 8.8)	1.9 (–0.6, 4.4)
	Rural	2003–2017	5.2* (2.2, 8.4)	–	–	5.2* (2.2, 8.4)	5.2* (2.2, 8.4)
50–64	All	2003–2017	8.2* (7.2, 9.3)	–	–	8.2* (7.2, 9.3)	8.2* (7.2, 9.3)
	Urban	2003–2017	9.9* (8.8, 11.1)	–	–	9.9* (8.8, 11.1)	9.9* (8.8, 11.1)
	Rural	2003–2015	1.2 (–0.8, 3.3)	2015–2017	23.3 (–12.3, 73.4)	4.1 (–0.5, 9.0)	11.7 (–3.8, 29.8)
>65	All	2003–2017	2.6* (1.3, 3.8)	–	–	2.6* (1.3, 3.8)	2.6* (1.3, 3.8)
	Urban	2003–2017	2.4* (1.0, 3.9)	–	–	2.4* (1.0, 3.9)	2.4* (1.0, 3.9)
	Rural	2003–2009	–6.3 (–12.5, 0.5)	2009–2017	9.8* (5.0, 14.8)	2.6 (–0.9, 6.2)	9.8* (5.0, 14.8)
All >20	All	2003–2017	5.1* (4.5, 5.6)	–	–	5.1* (4.5, 5.6)	5.1* (4.5, 5.6)
	Urban	2003–2017	5.5* (4.7, 6.3)	–	–	5.5* (4.7, 6.3)	5.5* (4.7, 6.3)
	Rural	2003–2015	2.4* (1.2, 3.6)	2015–2017	17.4 (–3.7, 43.0)	4.4* (1.7, 7.2)	9.6* (0.5, 19.6)

Abbreviation: APC=annual percent change; AAPC=average annual percent change; CI=confidence interval.

*APC or AAPC with statistically significant trends, $P < 0.05$.

SUPPLEMENTARY TABLE S5. The age-period-cohort estimates for cervical cancer incidence in China by area, 2003–2017.

Area	Factor	Coefficient (95% CI)	Risk ratio (95% CI)	Standard error	Z	P
All	Age_20	-2.19 (-2.54, -1.85)	0.11 (0.08, 0.16)	0.18	-12.48	<0.001
	Age_25	-0.75 (-0.9, -0.6)	0.47 (0.41, 0.55)	0.08	-9.81	<0.001
	Age_30	0.06 (-0.05, 0.17)	1.06 (0.96, 1.18)	0.05	1.13	0.257
	Age_35	0.33 (0.24, 0.42)	1.39 (1.27, 1.53)	0.05	6.85	<0.001
	Age_40	0.52 (0.44, 0.61)	1.69 (1.55, 1.84)	0.04	11.85	<0.001
	Age_45	0.55 (0.46, 0.64)	1.73 (1.59, 1.89)	0.04	12.48	<0.001
	Age_50	0.5 (0.41, 0.59)	1.65 (1.51, 1.81)	0.05	10.78	<0.001
	Age_55	0.42 (0.32, 0.52)	1.52 (1.38, 1.68)	0.05	8.24	<0.001
	Age_60	0.37 (0.26, 0.48)	1.44 (1.29, 1.61)	0.06	6.53	<0.001
	Age_65	0.33 (0.21, 0.44)	1.39 (1.23, 1.56)	0.06	5.41	<0.001
	Age_70	0.38 (0.26, 0.50)	1.47 (1.30, 1.65)	0.06	6.29	<0.001
	Age_75	0.12 (-0.01, 0.24)	1.13 (0.99, 1.28)	0.06	1.87	0.061
	Age_80	-0.07 (-0.21, 0.08)	0.94 (0.81, 1.08)	0.07	-0.89	0.372
	Age_85	-0.57 (-0.78, -0.37)	0.56 (0.46, 0.69)	0.1	-5.51	<0.001
	Period_2003	-0.33 (-0.36, -0.30)	0.72 (0.70, 0.74)	0.02	-20.38	<0.001
	Period_2008	0.07 (0.05, 0.10)	1.08 (1.05, 1.10)	0.01	5.94	<0.001
	Period_2013	0.25 (0.22, 0.28)	1.29 (1.25, 1.32)	0.01	17.88	<0.001
	Cohort_1918	0.91 (0.55, 1.26)	2.48 (1.73, 3.54)	0.18	4.98	<0.001
	Cohort_1923	0.5 (0.28, 0.71)	1.65 (1.33, 2.04)	0.11	4.57	<0.001
	Cohort_1928	0.23 (0.07, 0.38)	1.25 (1.08, 1.46)	0.08	2.91	0.004
	Cohort_1933	-0.08 (-0.22, 0.05)	0.92 (0.80, 1.05)	0.07	-1.20	0.229
	Cohort_1938	-0.18 (-0.31, -0.04)	0.84 (0.73, 0.96)	0.07	-2.52	0.012
	Cohort_1943	-0.14 (-0.27, 0)	0.87 (0.76, 1.00)	0.07	-1.94	0.052
	Cohort_1948	0.03 (-0.10, 0.16)	1.03 (0.90, 1.17)	0.07	0.39	0.693
	Cohort_1953	0.18 (0.06, 0.30)	1.2 (1.07, 1.36)	0.06	2.99	0.003
	Cohort_1958	0.32 (0.20, 0.43)	1.37 (1.23, 1.53)	0.06	5.52	<0.001
	Cohort_1963	0.5 (0.39, 0.60)	1.64 (1.48, 1.83)	0.05	9.27	<0.001
	Cohort_1968	0.39 (0.29, 0.50)	1.48 (1.34, 1.64)	0.05	7.47	<0.001
	Cohort_1973	0.18 (0.08, 0.29)	1.2 (1.08, 1.34)	0.05	3.44	0.001
	Cohort_1978	-0.15 (-0.27, -0.04)	0.86 (0.77, 0.96)	0.06	-2.62	0.009
Cohort_1983	-0.55 (-0.68, -0.41)	0.58 (0.51, 0.66)	0.07	-8.02	<0.001	
Cohort_1988	-0.93 (-1.16, -0.71)	0.39 (0.31, 0.49)	0.11	-8.26	<0.001	
Cohort_1993	-1.2 (-1.89, -0.5)	0.3 (0.15, 0.61)	0.36	-3.36	0.001	

TABLE S5. (Continued)

Area	Factor	Coefficient (95% CI)	Risk ratio (95% CI)	Standard error	Z	P
	Age_20	-2.13 (-2.44, -1.82)	0.12 (0.09, 0.16)	0.16	-13.62	<0.001
	Age_25	-0.68 (-0.81, -0.55)	0.51 (0.44, 0.58)	0.07	-9.99	<0.001
	Age_30	0.11 (0.01, 0.20)	1.11 (1.01, 1.22)	0.05	2.20	0.028
	Age_35	0.34 (0.26, 0.43)	1.41 (1.3, 1.53)	0.04	8.03	<0.001
	Age_40	0.49 (0.42, 0.57)	1.64 (1.52, 1.77)	0.04	12.54	<0.001
	Age_45	0.5 (0.43, 0.58)	1.66 (1.53, 1.79)	0.04	12.82	<0.001
	Age_50	0.44 (0.36, 0.52)	1.55 (1.43, 1.69)	0.04	10.60	<0.001
	Age_55	0.35 (0.26, 0.44)	1.42 (1.30, 1.56)	0.05	7.64	<0.001
	Age_60	0.31 (0.21, 0.41)	1.37 (1.24, 1.51)	0.05	6.17	<0.001
	Age_65	0.32 (0.21, 0.43)	1.38 (1.24, 1.53)	0.05	5.89	<0.001
	Age_70	0.36 (0.25, 0.46)	1.43 (1.28, 1.59)	0.05	6.51	<0.001
	Age_75	0.12 (0.01, 0.23)	1.13 (1.01, 1.26)	0.06	2.06	0.039
	Age_80	-0.03 (-0.16, 0.10)	0.97 (0.85, 1.11)	0.07	-0.44	0.66
	Age_85	-0.51 (-0.69, -0.33)	0.6 (0.50, 0.72)	0.09	-5.56	<0.001
	Period_2003	-0.31 (-0.34, -0.29)	0.73 (0.71, 0.75)	0.01	-21.93	<0.001
	Period_2008	0.08 (0.06, 0.10)	1.09 (1.06, 1.11)	0.01	7.36	<0.001
Urban	Period_2013	0.23 (0.21, 0.26)	1.26 (1.23, 1.29)	0.01	18.30	<0.001
	Cohort_1918	0.88 (0.56, 1.19)	2.41 (1.76, 3.29)	0.16	5.50	<0.001
	Cohort_1923	0.45 (0.26, 0.64)	1.57 (1.30, 1.90)	0.1	4.65	<0.001
	Cohort_1928	0.21 (0.07, 0.34)	1.23 (1.07, 1.41)	0.07	2.97	0.003
	Cohort_1933	-0.13 (-0.26, -0.01)	0.88 (0.77, 0.99)	0.06	-2.06	0.039
	Cohort_1938	-0.18 (-0.31, -0.06)	0.83 (0.73, 0.94)	0.06	-2.90	0.004
	Cohort_1943	-0.12 (-0.24, 0.01)	0.89 (0.79, 1.01)	0.06	-1.83	0.067
	Cohort_1948	0.04 (-0.08, 0.16)	1.04 (0.92, 1.17)	0.06	0.61	0.544
	Cohort_1953	0.24 (0.13, 0.35)	1.27 (1.14, 1.42)	0.06	4.33	<0.001
	Cohort_1958	0.4 (0.30, 0.50)	1.5 (1.35, 1.66)	0.05	7.75	<0.001
	Cohort_1963	0.58 (0.48, 0.67)	1.78 (1.62, 1.96)	0.05	11.85	<0.001
	Cohort_1968	0.47 (0.38, 0.56)	1.6 (1.46, 1.76)	0.05	9.85	<0.001
	Cohort_1973	0.24 (0.15, 0.34)	1.27 (1.16, 1.40)	0.05	4.95	<0.001
	Cohort_1978	-0.14 (-0.24, -0.03)	0.87 (0.79, 0.97)	0.05	-2.56	0.011
	Cohort_1983	-0.62 (-0.74, -0.50)	0.54 (0.48, 0.61)	0.06	-9.98	<0.001
	Cohort_1988	-0.96 (-1.16, -0.76)	0.38 (0.31, 0.47)	0.1	-9.38	<0.001
	Cohort_1993	-1.36 (-2.03, -0.69)	0.26 (0.13, 0.50)	0.34	-3.98	<0.001

TABLE S5. (Continued)

Area	Factor	Coefficient (95% CI)	Risk ratio (95% CI)	Standard error	Z	P
	Age_20	-2.55 (-3.41, -1.69)	0.08 (0.03, 0.18)	0.44	-5.81	<0.001
	Age_25	-1.16 (-1.54, -0.78)	0.31 (0.21, 0.46)	0.19	-5.96	<0.001
	Age_30	-0.22 (-0.49, 0.05)	0.8 (0.61, 1.06)	0.14	-1.57	0.116
	Age_35	0.23 (-0.02, 0.47)	1.26 (0.98, 1.61)	0.12	1.84	0.066
	Age_40	0.7 (0.48, 0.92)	2.02 (1.62, 2.51)	0.11	6.25	<0.001
	Age_45	0.82 (0.61, 1.04)	2.28 (1.84, 2.82)	0.11	7.48	<0.001
	Age_50	0.86 (0.64, 1.08)	2.37 (1.89, 2.96)	0.11	7.59	<0.001
	Age_55	0.85 (0.62, 1.09)	2.35 (1.85, 2.98)	0.12	7.06	<0.001
	Age_60	0.68 (0.43, 0.94)	1.98 (1.54, 2.56)	0.13	5.28	<0.001
	Age_65	0.39 (0.11, 0.66)	1.47 (1.12, 1.94)	0.14	2.74	0.006
	Age_70	0.52 (0.24, 0.79)	1.68 (1.27, 2.21)	0.14	3.67	<0.001
	Age_75	0.14 (-0.16, 0.43)	1.14 (0.85, 1.54)	0.15	0.89	0.376
	Age_80	-0.28 (-0.63, 0.08)	0.76 (0.53, 1.08)	0.18	-1.54	0.124
	Age_85	-0.99 (-1.54, -0.44)	0.37 (0.21, 0.65)	0.28	-3.52	<0.001
	Period_2003	-0.41 (-0.49, -0.34)	0.66 (0.61, 0.71)	0.04	-10.42	<0.001
	Period_2008	0.03 (-0.03, 0.09)	1.03 (0.97, 1.10)	0.03	1.00	0.315
Rural	Period_2013	0.38 (0.32, 0.45)	1.46 (1.37, 1.56)	0.03	11.35	<0.001
	Cohort_1918	1.1 (0.08, 2.12)	3 (1.09, 8.31)	0.52	2.12	0.034
	Cohort_1923	0.82 (0.28, 1.36)	2.27 (1.33, 3.9)	0.28	2.99	0.003
	Cohort_1928	0.36 (-0.02, 0.75)	1.44 (0.98, 2.11)	0.2	1.86	0.063
	Cohort_1933	0.22 (-0.11, 0.55)	1.24 (0.90, 1.72)	0.17	1.30	0.193
	Cohort_1938	-0.11 (-0.43, 0.22)	0.9 (0.65, 1.25)	0.17	-0.64	0.522
	Cohort_1943	-0.24 (-0.55, 0.08)	0.79 (0.58, 1.08)	0.16	-1.46	0.144
	Cohort_1948	-0.05 (-0.35, 0.25)	0.95 (0.70, 1.28)	0.15	-0.35	0.723
	Cohort_1953	-0.14 (-0.42, 0.14)	0.87 (0.66, 1.15)	0.14	-1.00	0.32
	Cohort_1958	-0.2 (-0.47, 0.06)	0.82 (0.63, 1.06)	0.13	-1.52	0.128
	Cohort_1963	0.04 (-0.21, 0.28)	1.04 (0.81, 1.33)	0.13	0.29	0.772
	Cohort_1968	-0.02 (-0.27, 0.22)	0.98 (0.77, 1.25)	0.12	-0.19	0.852
	Cohort_1973	-0.12 (-0.37, 0.13)	0.89 (0.69, 1.14)	0.13	-0.91	0.361
	Cohort_1978	-0.23 (-0.50, 0.05)	0.8 (0.60, 1.05)	-1.59	0.112	
	Cohort_1983	-0.12 (-0.43, 0.20)	0.89 (0.65, 1.22)	0.16	-0.73	0.468
	Cohort_1988	-0.77 (-1.29, -0.24)	0.46 (0.27, 0.79)	0.27	-2.85	0.004
	Cohort_1993	-0.55 (-1.89, 0.79)	0.58 (0.15, 2.21)	0.68	-0.80	0.423

SUPPLEMENTARY TABLE S6. The age-period-cohort estimates for cervical cancer mortality in China by area, 2003–2017.

Area	Factor	Coefficient (95% CI)	Risk ratio (95% CI)	Standard Error	Z	P
All	Age_20	-2.11 (-2.55, -1.67)	0.12 (0.08, 0.19)	0.22	-9.44	<0.001
	Age_25	-1.57 (-1.82, -1.32)	0.21 (0.16, 0.27)	0.13	-12.15	<0.001
	Age_30	-0.78 (-0.95, -0.61)	0.46 (0.39, 0.54)	0.09	-8.94	<0.001
	Age_35	-0.27 (-0.42, -0.12)	0.77 (0.66, 0.89)	0.08	-3.5	<0.001
	Age_40	-0.02 (-0.15, 0.12)	0.98 (0.86, 1.12)	0.07	-0.29	0.774
	Age_45	0.29 (0.16, 0.41)	1.33 (1.18, 1.51)	0.06	4.58	<0.001
	Age_50	0.37 (0.25, 0.48)	1.44 (1.29, 1.62)	0.06	6.27	<0.001
	Age_55	0.4 (0.29, 0.51)	1.49 (1.34, 1.67)	0.06	7.15	<0.001
	Age_60	0.39 (0.28, 0.49)	1.47 (1.32, 1.64)	0.05	7.05	<0.001
	Age_65	0.47 (0.37, 0.57)	1.6 (1.44, 1.77)	0.05	8.99	<0.001
	Age_70	0.65 (0.56, 0.75)	1.92 (1.74, 2.11)	0.05	13.51	<0.001
	Age_75	0.72 (0.63, 0.81)	2.06 (1.88, 2.26)	0.05	15.52	<0.001
	Age_80	0.77 (0.67, 0.87)	2.16 (1.95, 2.40)	0.05	14.77	<0.001
	Age_85	0.69 (0.56, 0.82)	1.99 (1.75, 2.27)	0.07	10.53	<0.001
	Period_2003	-0.35 (-0.39, -0.31)	0.71 (0.68, 0.73)	0.02	-18.49	<0.001
	Period_2008	0.01 (-0.02, 0.04)	1.01 (0.98, 1.04)	0.01	0.88	0.377
	Period_2013	0.34 (0.30, 0.37)	1.4 (1.35, 1.44)	0.02	20.82	<0.001
	Cohort_1918	1.28 (1.07, 1.50)	3.61 (2.91, 4.47)	0.11	11.69	<0.001
	Cohort_1923	1.21 (1.06, 1.36)	3.34 (2.88, 3.88)	0.08	15.79	<0.001
	Cohort_1928	0.78 (0.65, 0.90)	2.17 (1.92, 2.47)	0.06	12.00	<0.001
	Cohort_1933	0.45 (0.33, 0.57)	1.57 (1.39, 1.77)	0.06	7.20	<0.001
	Cohort_1938	0.23 (0.10, 0.36)	1.26 (1.11, 1.43)	0.07	3.54	<0.001
	Cohort_1943	0.07 (-0.07, 0.21)	1.07 (0.93, 1.23)	0.07	0.97	0.333
	Cohort_1948	0.13 (-0.02, 0.27)	1.14 (0.98, 1.32)	0.07	1.71	0.086
	Cohort_1953	0.13 (-0.02, 0.28)	1.14 (0.98, 1.32)	0.08	1.66	0.097
	Cohort_1958	0.24 (0.09, 0.40)	1.27 (1.09, 1.49)	0.08	3.03	0.002
	Cohort_1963	0.36 (0.19, 0.52)	1.43 (1.21, 1.68)	0.08	4.25	<0.001
	Cohort_1968	0.24 (0.07, 0.41)	1.27 (1.07, 1.51)	0.09	2.72	0.007
Cohort_1973	-0.04 (-0.23, 0.14)	0.96 (0.80, 1.15)	0.09	-0.45	0.65	
Cohort_1978	-0.38 (-0.58, -0.17)	0.69 (0.56, 0.84)	0.10	-3.65	<0.001	
Cohort_1983	-0.72 (-0.95, -0.49)	0.49 (0.39, 0.61)	0.12	-6.17	<0.001	
Cohort_1988	-1.24 (-1.63, -0.86)	0.29 (0.20, 0.42)	0.20	-6.35	<0.001	
Cohort_1993	-2.72 (-4.15, -1.30)	0.07 (0.02, 0.27)	0.73	-3.74	<0.001	

TABLE S6. (Continued)

Area	Factor	Coefficient (95% CI)	Risk ratio (95% CI)	Standard Error	Z	P
	Age_20	-2.13 (-2.50, -1.76)	0.12 (0.08, 0.17)	0.19	-11.34	<0.001
	Age_25	-1.58 (-1.79, -1.37)	0.21 (0.17, 0.26)	0.11	-14.51	<0.001
	Age_30	-0.72 (-0.86, -0.58)	0.48 (0.42, 0.56)	0.07	-10.11	<0.001
	Age_35	-0.23 (-0.36, -0.11)	0.79 (0.70, 0.89)	0.06	-3.74	<0.001
	Age_40	-0.06 (-0.17, 0.06)	0.95 (0.85, 1.06)	0.06	-0.98	0.326
	Age_45	0.25 (0.15, 0.35)	1.29 (1.17, 1.43)	0.05	4.95	<0.001
	Age_50	0.31 (0.21, 0.40)	1.36 (1.24, 1.49)	0.05	6.42	<0.001
	Age_55	0.33 (0.24, 0.42)	1.39 (1.27, 1.52)	0.05	7.12	<0.001
	Age_60	0.31 (0.22, 0.4)	1.37 (1.25, 1.50)	0.05	6.82	<0.001
	Age_65	0.48 (0.4, 0.57)	1.62 (1.49, 1.77)	0.04	11.13	<0.001
	Age_70	0.71 (0.63, 0.78)	2.03 (1.87, 2.19)	0.04	17.82	<0.001
	Age_75	0.74 (0.67, 0.82)	2.1 (1.95, 2.27)	0.04	19.44	<0.001
	Age_80	0.85 (0.77, 0.93)	2.34 (2.15, 2.54)	0.04	20.14	<0.001
	Age_85	0.74 (0.64, 0.84)	2.1 (1.89, 2.33)	0.05	14.10	<0.001
	Period_2003	-0.38 (-0.41, -0.35)	0.68 (0.66, 0.71)	0.02	-24.50	<0.001
	Period_2008	0.03 (0.01, 0.05)	1.03 (1.01, 1.06)	0.01	2.56	0.011
Urban	Period_2013	0.35 (0.32, 0.38)	1.42 (1.38, 1.46)	0.01	26.44	<0.001
	Cohort_1918	1.38 (1.21, 1.56)	3.99 (3.35, 4.76)	0.09	15.40	<0.001
	Cohort_1923	1.29 (1.16, 1.42)	3.65 (3.20, 4.15)	0.07	19.60	<0.001
	Cohort_1928	0.76 (0.65, 0.88)	2.15 (1.91, 2.41)	0.06	13.04	<0.001
	Cohort_1933	0.41 (0.30, 0.53)	1.51 (1.35, 1.69)	0.06	7.26	<0.001
	Cohort_1938	0.18 (0.06, 0.30)	1.2 (1.06, 1.34)	0.06	2.99	0.003
	Cohort_1943	0.01 (-0.12, 0.14)	1.01 (0.89, 1.15)	0.07	0.15	0.88
	Cohort_1948	0.09 (-0.04, 0.22)	1.1 (0.96, 1.25)	0.07	1.36	0.174
	Cohort_1953	0.2 (0.06, 0.34)	1.22 (1.07, 1.40)	0.07	2.88	0.004
	Cohort_1958	0.37 (0.23, 0.51)	1.45 (1.26, 1.67)	0.07	5.17	<0.001
	Cohort_1963	0.48 (0.34, 0.63)	1.62 (1.40, 1.88)	0.07	6.47	<0.001
	Cohort_1968	0.33 (0.18, 0.49)	1.4 (1.20, 1.63)	0.08	4.25	<0.001
	Cohort_1973	0.03 (-0.13, 0.20)	1.04 (0.88, 1.22)	0.08	0.42	0.678
	Cohort_1978	-0.42 (-0.60, -0.24)	0.66 (0.55, 0.79)	0.09	-4.62	<0.001
	Cohort_1983	-0.75 (-0.94, -0.55)	0.47 (0.39, 0.58)	0.10	-7.41	<0.001
	Cohort_1988	-1.28 (-1.61, -0.95)	0.28 (0.20, 0.39)	0.17	-7.60	<0.001
	Cohort_1993	-3.12 (-4.56, -1.68)	0.04 (0.01, 0.19)	0.73	-4.25	<0.001

TABLE S6. (Continued)

Area	Factor	Coefficient (95% CI)	Risk ratio (95% CI)	Standard Error	Z	P
	Age_20	-1.96 (-3.25, -0.67)	0.14 (0.04, 0.51)	0.66	-2.98	0.003
	Age_25	-1.55 (-2.29, -0.81)	0.21 (0.10, 0.45)	0.38	-4.09	<0.001
	Age_30	-0.95 (-1.52, -0.39)	0.39 (0.22, 0.68)	0.29	-3.32	0.001
	Age_35	-0.38 (-0.86, 0.10)	0.68 (0.42, 1.11)	0.25	-1.54	0.123
	Age_40	0.15 (-0.29, 0.59)	1.17 (0.75, 1.81)	0.22	0.69	0.492
	Age_45	0.38 (-0.02, 0.79)	1.47 (0.98, 2.20)	0.21	1.87	0.062
	Age_50	0.55 (0.17, 0.93)	1.74 (1.19, 2.54)	0.19	2.86	0.004
	Age_55	0.62 (0.26, 0.97)	1.86 (1.30, 2.65)	0.18	3.42	0.001
	Age_60	0.59 (0.26, 0.92)	1.8 (1.29, 2.51)	0.17	3.48	0.001
	Age_65	0.44 (0.12, 0.76)	1.55 (1.13, 2.13)	0.16	2.70	0.007
	Age_70	0.49 (0.19, 0.80)	1.64 (1.2, 2.23)	0.16	3.14	0.002
	Age_75	0.7 (0.40, 1.00)	2.01 (1.49, 2.71)	0.15	4.59	<0.001
	Age_80	0.47 (0.10, 0.84)	1.6 (1.11, 2.32)	0.19	2.49	0.013
	Age_85	0.45 (-0.03, 0.93)	1.56 (0.97, 2.52)	0.24	1.82	0.068
	Period_2003	-0.25 (-0.37, -0.13)	0.78 (0.69, 0.88)	0.06	-4.08	<0.001
	Period_2008	-0.07 (-0.17, 0.04)	0.94 (0.84, 1.04)	0.05	-1.25	0.21
Rural	Period_2013	0.31 (0.21, 0.42)	1.37 (1.23, 1.52)	0.05	5.93	<0.001
	Cohort_1918	0.89 (0.02, 1.76)	2.43 (1.02, 5.80)	0.44	2.00	0.045
	Cohort_1923	0.68 (0.10, 1.25)	1.97 (1.11, 3.51)	0.29	2.31	0.021
	Cohort_1928	0.95 (0.57, 1.34)	2.59 (1.76, 3.81)	0.20	4.84	<0.001
	Cohort_1933	0.72 (0.35, 1.08)	2.05 (1.43, 2.96)	0.19	3.86	<0.001
	Cohort_1938	0.54 (0.18, 0.90)	1.72 (1.19, 2.47)	0.19	2.90	0.004
	Cohort_1943	0.34 (-0.06, 0.74)	1.4 (0.94, 2.09)	0.20	1.68	0.093
	Cohort_1948	0.34 (-0.07, 0.75)	1.41 (0.93, 2.12)	0.21	1.63	0.103
	Cohort_1953	0.05 (-0.38, 0.48)	1.05 (0.68, 1.62)	0.22	0.22	0.826
	Cohort_1958	-0.13 (-0.59, 0.33)	0.88 (0.55, 1.39)	0.24	-0.55	0.584
	Cohort_1963	-0.06 (-0.55, 0.42)	0.94 (0.58, 1.52)	0.25	-0.26	0.793
	Cohort_1968	-0.05 (-0.56, 0.46)	0.95 (0.57, 1.58)	0.26	-0.20	0.841
	Cohort_1973	-0.33 (-0.88, 0.22)	0.72 (0.41, 1.25)	0.28	-1.17	0.242
	Cohort_1978	-0.16 (-0.74, 0.43)	0.86 (0.48, 1.53)	0.30	-0.52	0.602
	Cohort_1983	-0.56 (-1.27, 0.15)	0.57 (0.28, 1.16)	0.36	-1.54	0.123
	Cohort_1988	-1.1 (-2.19, 0)	0.33 (0.11, 1.00)	0.56	-1.96	0.05
	Cohort_1993	-2.12 (-5.25, 1.01)	0.12 (0.01, 2.74)	1.60	-1.33	0.184

Preplanned Studies

Cervical Cancer Screening Coverage — China, 2018–2019

Mei Zhang^{1,✉}; Yijing Zhong^{2,✉}; Limin Wang¹; Heling Bao⁴; Zhengjing Huang¹; Zhenping Zhao¹; Xiao Zhang¹; Chun Li¹; Kelly Liang Sun⁵; Jing Wu^{6,✉}; Xiaoying Zheng^{2,✉}; Linhong Wang^{3,✉}

Summary**What is already known about this topic?**

The World Health Organization set a 2030 target of 70% cervical cancer screening coverage for women aged 35–45 years. Coverage stood at 37% in China in 2015.

What is added by this report?

In 2018–2019, China's cervical cancer screening coverage reached 43.4% in women aged 35–44 years and 36.8% in women aged 35–64 years. Screening coverage was still lower in rural areas as well as central and western regions; large variations existed across provincial-level administrative divisions.

What are the implications for public health practice?

National and local policy and financial support should be maintained for cervical cancer screening, along with more targeted health education and outreach efforts and strengthened accessibility of health services in the rural areas and central and western regions.

Effective prevention and control measures have tamed cervical cancer in most parts of the world. In November 2020, the World Health Organization (WHO) set a 2030 target of 70% cervical cancer screening coverage for women aged 35–45 years. (1) China launched a national free screening program for rural women aged 35–64 years in 2009, in order to combat rising cervical cancer incidence, particularly in younger and rural populations, since the late 1990s (2) and an imbalanced disease burden in the central and western regions (3). It set a goal that screening coverage should reach 50% in women aged 35–64 years by 2025 (4). This study used the latest nationally and provincially representative survey data to estimate screening coverage in China and analyze its key sociodemographic and geographic factors via Rao Scott chi-square tests and logistic regression models. This study still suggests gaps in cervical cancer screening coverage with the WHO 2030 target. It also suggests that national and local policy and financial support should be maintained, health education and outreach

efforts should be directed more toward the targeted age groups, and accessibility of health-related services should be further strengthened in the rural areas and central and western regions.

This study estimated China's latest cervical cancer screening uptake by using newly released national survey data from China Chronic Disease and Nutrition Surveillance in 2018–2019. Women aged 18 years and older were selected from 298 districts/counties across all 31 provincial-level administrative divisions (PLADs) in the mainland of China through multi-stage and cluster randomized sampling. Women were interviewed by trained local health staff about history of previous cervical cancer screening as well as the month and year of the most recent screening, if applicable. A total of 102,779 participants aged 20–64 years old completed the survey, yielding a 95.0% response rate. Among them, 27,471 female participants were excluded from the final analysis because of incomplete sociodemographic data, lack of response to the cervical cancer screening question, or age falling outside the targeted age groups. The screening rates of stratified sociodemographic groups were compared through chi-square tests, and predictors of screening uptake were investigated via multivariate logistic regression analysis. Standard errors (SE) were estimated by Taylor linearization with a finite population correction. Statistical significance was determined using two-sided $P < 0.05$. All statistical analyses were performed over SAS (version 9.4, SAS Institute Inc., Cary, USA).

The final sample consists of 75,308 participants aged 20–64 years old. Participants were 40 years old on average with 44.6% from urban areas, 42.2% from the eastern region of China, 96.9% with health insurance coverage, and 43.8% with health check-ups done in the previous three years (Table 1).

The estimated results show that in 2018–2019, cervical cancer lifetime screening coverage (i.e., the percentage of women who had ever taken screening) reached 43.4% [95% confidence interval (CI): 41.5%–45.3%] in women aged 35–44 years, 39.6%

TABLE 1. Sociodemographic characteristics of female participants aged 20–64 years in the cervical cancer screening survey — China, 2018–2019.

Characteristics	No. of participants (N=72,095)	Weighted proportion (%)*
Age (years)		
20–24	1,534	15.9
25–34	8,318	22.0
35–44	12,163	26.7
45–54	24,840	20.0
55–64	25,240	15.2
Area type		
Urban	33,068	44.6
Rural	39,027	55.4
Location		
Eastern	26,674	42.2
Central	21,147	32.4
Western	24,274	25.3
Education		
Primary or less	34,596	31.6
Middle school	21,781	32.3
High school	9,553	16.1
College or above	6,165	20.0
Income (CNY)		
Q1 (<6,667)	15,278	18.3
Q2 (6,667–13,332)	13,943	18.0
Q3 (13,333–27,999)	13,355	19.2
Q4 (28,000+)	14,142	23.0
Don't know/refused	15,377	21.5
Employment		
Employed	47,155	69.1
Housework	14,835	18.3
Retired	6,541	4.3
Unemployed	3,564	8.3
With health insurance		
No	1,462	3.1
Yes	70,633	96.9
With health check-ups in the past 3 years		
No	40,195	51.9
Yes	31,900	48.1
Self-assessed health status		
Poor or fair	41,913	56.5
Good	30,182	43.5

* Percentages are weighted to represent the national total population with poststratification for age and gender.

(95% CI: 37.9%–41.4%) in women aged 30–49 years, and 36.8% (95% CI: 35.1%–38.4%) in women aged 35–64 years. (Table 2) Screening coverage peaked at

45.0% in the 40–44 age group and declined to 18.8% in the 60–64 age group. About 90% of the screened women reported doing so within the previous three

TABLE 2. Sociodemographic stratifications and multivariate logistic regression results of cervical cancer screening coverage in China, 2018–2019.

Sociodemographic variables	Screen rates among 20–64 years old % (95% CI)			P-value*	35–64 years old	
	Total	Urban	Rural		Screen rates % (95% CI)	Screen OR (95% CI)
Total	29.5 (28.1, 30.9)	32.2 (30.2, 34.2)	26.6 (24.9, 28.3)	<0.001	36.8 (35.1, 38.4)	
Age (years)						
20–24	8.6 (6.6, 10.6)	7.8 (4.8, 10.9)	9.5 (6.7, 12.3)	0.473	–	–
25–29	19.2 (17.0, 21.3)	21.8 (18.5, 25.1)	15.7 (13.7, 17.7)	0.001	–	–
30–34	29.7 (27.3, 32.1)	32.3 (29.0, 35.6)	26.1 (22.9, 29.3)	0.012	–	–
35–39	41.7 (39.3, 44.1)	47.3 (44.0, 50.5)	34.9 (31.7, 38.2)	<0.001	41.7 (39.3, 44.1)	2.82 (2.48, 3.22)
40–44	45.0 (42.7, 47.2)	48.3 (44.9, 51.6)	41.6 (38.8, 44.3)	0.002	45.0 (42.7, 47.2)	3.51 (3.10, 3.98)
45–49	40.1 (37.8, 42.4)	43.6 (40.4, 46.7)	36.7 (33.7, 39.6)	0.001	40.1 (37.8, 42.4)	3.02 (2.69, 3.39)
50–54	34.5 (32.5, 36.4)	38.6 (35.8, 41.4)	30.4 (27.7, 33.2)	<0.001	34.5 (32.5, 36.4)	2.33 (2.13, 2.55)
55–59	27.5 (25.6, 29.3)	30.9 (27.9, 33.9)	24.5 (22.2, 26.7)	0.001	27.5 (25.6, 29.3)	1.60 (1.48, 1.74)
60–64	18.8 (17.2, 20.5)	21.4 (19.0, 23.8)	16.7 (14.6, 18.8)	0.005	18.8 (17.2, 20.5)	1.00 [Reference]
P_{trend}	<0.001	<0.001	<0.001		<0.001	
30–49	39.6 (37.9, 41.4)	43.2 (40.7, 45.6)	35.6 (33.6, 37.7)	<0.001	–	–
35–44	43.4 (41.4, 45.3)	47.8 (44.9, 50.6)	38.5 (36.3, 40.7)	<0.001	–	–
Area type						
Urban	32.2 (30.2, 34.2)	–	–		41.1 (38.7, 43.4)	0.92 (0.81, 1.00)
Rural	26.6 (24.9, 28.3)	–	–		32.4 (30.5, 34.4)	1.00 [Reference]
$P_{\text{difference}}$	<0.001				<0.001	
Geographic region						
Eastern	33.4 (31.1, 35.7)	36.0 (33.1, 39.0)	29.3 (26.6, 32.0)	<0.001	41.6 (38.9, 44.3)	1.31 (1.12, 1.53)
Central	28.1 (25.5, 30.7)	29.9 (25.9, 33.9)	26.6 (23.1, 30.0)	0.242	34.9 (31.9, 38.0)	1.11 (0.93, 1.32)
Western	24.8 (23.1, 26.6)	26.6 (24.0, 29.2)	23.4 (21.3, 25.6)	0.070	31.3 (28.9, 33.6)	1.00 [Reference]
$P_{\text{difference}}$	<0.001	<0.001	0.023		<0.001	
Education						
Primary or less	25.3 (23.6, 26.9)	26.4 (23.4, 29.3)	24.8 (23.0, 26.6)	0.348	26.9 (25.2, 28.6)	1.00 [Reference]
Middle school	32.1 (30.1, 34.0)	35.3 (32.4, 38.3)	29.2 (27.1, 31.4)	<0.001	40.2 (38.2, 42.3)	1.53 (1.40, 1.67)
High school	33.5 (30.9, 36.1)	36.0 (32.9, 39.1)	28.1 (23.5, 32.8)	0.011	46.5 (42.9, 50.1)	1.81 (1.58, 2.08)
College or above	28.9 (26.3, 31.5)	30.2 (27.2, 33.2)	22.4 (18.3, 26.6)	0.006	55.7 (51.9, 59.4)	1.85 (1.56, 2.20)
P_{trend}	0.005	0.489	0.493		<0.001	
Household income per capita (CNY)						
Q1 (<6,667)	24.2 (22.3, 26.1)	24.8 (20.0, 29.5)	24.0 (22.0, 26.0)	0.783	29.7 (27.5, 31.8)	1.00 [Reference]
Q2 (6,667–13,332)	27.6 (25.7, 29.5)	29.6 (27.3, 31.9)	26.0 (23.4, 28.6)	0.038	34.2 (32.2, 36.1)	1.09 (0.97, 1.23)
Q3 (13,333–27,999)	32.4 (30.4, 34.4)	34.0 (31.2, 36.7)	30.2 (27.6, 32.8)	0.054	40.2 (37.9, 42.4)	1.15 (1.01, 1.31)
Q4 (>28,000)	36.3 (33.9, 38.7)	37.2 (34.4, 40.1)	33.1 (29.5, 36.6)	0.085	47.3 (44.6, 50.1)	1.24 (1.07, 1.43)
Don't know/refused	26.1 (23.9, 28.3)	28.0 (24.7, 31.4)	24.2 (21.7, 26.8)	0.075	31.8 (28.8, 34.8)	0.92 (0.80, 1.06)
$P_{\text{trend}}^{\dagger}$	<0.001	<0.001	<0.001		<0.001	
Employment status						
Employed	30.5 (29.1, 31.9)	33.4 (31.2, 35.5)	27.6 (25.9, 29.2)	<0.001	37.9 (36.2, 39.5)	1.11 (0.96, 1.28)
Housework	28.5 (25.9, 31.1)	32.4 (28.5, 36.2)	25.7 (23.1, 28.4)	0.001	33.0 (30.4, 35.6)	1.10 (0.94, 1.30)
Retired	35.3 (31.7, 38.9)	35.0 (31.3, 38.6)	45.5 (35.8, 55.2)	0.034	35.8 (32.2, 39.4)	1.00 [Reference]
Unemployed	20.3 (17.6, 23.0)	21.7 (18.1, 25.3)	18.1 (14.0, 22.1)	0.215	37.0 (32.4, 41.5)	1.07 (0.84, 1.38)
$P_{\text{difference}}$	<0.001	<0.001	<0.001		0.002	

TABLE 2. (Continued)

Sociodemographic variables	Screen rates among 20–64 years old % (95% CI)			P-value*	35–64 years old	
	Total	Urban	Rural		Screen rates % (95% CI)	Screen OR (95% CI)
Health insurance						
No	15.4 (11.9, 18.9)	15.9 (11.5, 20.3)	14.4 (9.1, 19.7)	0.678	21.3 (17.3, 25.4)	1.00 [Reference]
Yes	30.0 (28.6, 31.4)	32.9 (30.9, 34.8)	26.9 (25.1, 28.6)	<0.001	37.1 (35.4, 38.7)	1.96 (1.57, 2.45)
<i>P</i> _{difference}	<0.001	<0.001	0.001		<0.001	
Health check-up in the last 3 years						
No	20.2 (18.8, 21.5)	20.5 (18.3, 22.7)	19.9 (18.4, 21.4)	0.654	24.5 (22.8, 26.1)	1.00 [Reference]
Yes	40.8 (39.1, 42.5)	42.0 (39.8, 44.2)	38.8 (36.2, 41.4)	0.066	51.4 (49.3, 53.2)	3.09 (2.84, 3.36)
<i>P</i> _{difference}	<0.001	<0.001	<0.001		<0.001	
Self-assessed health						
Poor or fair	31.4 (29.9, 32.9)	34.5 (32.2, 36.9)	28.3 (26.7, 29.9)	<0.001	37.2 (35.5, 38.8)	1.00 [Reference]
Good	27.5 (25.9, 29.1)	29.9 (27.9, 32.0)	24.5 (22.3, 26.7)	0.001	36.2 (34.1, 38.3)	0.85 (0.78, 0.93)
<i>P</i> _{difference}	<0.001	<0.001	<0.001		0.349	

Note: Screening rates are all weighted proportions to represent the national total population with poststratification for age and gender.

Abbreviation: OR=odds ratio; CI=confidence interval.

* *P*-value denotes *P*-value for difference between urban screening coverage and rural screening coverage in women aged 20–64 years.

† Participants answering “Don’t know/refused” are not included in the calculation.

years.

Low screening uptake for the 20–64 age groups was found in women with the lowest education (25.3%; 95% CI: 23.6%–26.9%), income (24.2%; 95% CI: 22.3%–26.1%), without health insurance coverage (15.4%; 95% CI: 11.9%–18.9%), without health check-ups in the previous three years (20.2%; 95% CI: 18.8%–21.5%), and in the 20–24 age group (urban, 7.8%; 95% CI: 4.8%–10.9%, vs. rural, 9.5%; 95% CI: 6.7%–12.3%). Screening coverage for women aged 35–64 years in urban areas was 45.6% (95% CI: 42.0%–49.2%) in the eastern region, 37.9% (95% CI: 33.3%–42.5%) in the central region, and 35.3% (95% CI: 32.1%–38.5%) in the western region; for rural women aged 35–64 years, it was 36.0% (95% CI: 32.9%–39.1%) in the eastern region, 32.4% (95% CI: 28.5%–36.3%) in the central region, and 28.3% (95% CI: 25.8%–30.9%) in the western region.

Multivariate logistic regression results for women aged 35–64 years surprisingly revealed that the urban factor was statistically insignificant, if not negative, in predicting screening uptake compared to the rural areas [odds ratio (OR): 0.92; 95% CI: 0.81–1.00]. However, the likelihood of screening in the eastern region still prevailed over the western region (OR: 1.31; 95% CI: 1.12–1.53), whereas the central region showed an insignificant advantage over the western region (OR: 1.11; 95% CI: 0.93–1.32). The likelihood of screening was 96% higher in women with health insurance than in women without health insurance (OR: 1.96; 95%

CI: 1.57–2.45), and 2.09 times higher in women with health check-ups during the past three years than in women without health check-ups (OR: 3.09; 95% CI: 2.84–3.36).

PLADs’ data showed that Beijing Municipality went beyond 70% in screening coverage, followed by Zhejiang Province at above 60%, Jiangsu Province at above 50%, Tianjin Municipality, Hunan Province, and Shanghai Municipality at nearly 50%, while Hebei Province, Xizang (Tibet) Autonomous Region and Guizhou Province fell under 25% in screening coverage (Figure 1).

DISCUSSION

This study estimated that in 2018–2019, 43.4% of women aged 35–44 years, 39.6% of women aged 30–49 years, and 36.8% of women aged 35–64 years had ever participated in cervical cancer screening in China. These results reveal both progress and gaps in cervical cancer screening in China. On the one hand, screening coverage for women aged 35–64 years, the targeted range of China’s national screening program, rose continuously from about 25% in 2010 (5), 27% in 2013 (6), 31% in 2015 (7), to the current 37% in 2018–2019. The upward trend provides strong evidence for the positive impact of the national screening program. Screening coverage for women aged 30–49 years, the age groups recommended by the



FIGURE 1. Provincial-level administrative divisions variations of cervical cancer screening coverage in women aged 35–64 years in China, 2018–2019.

WHO to monitor screening performance and results (1), also slightly exceeds the estimated worldwide screening coverage of 36% in 2019 (8). On the other hand, the 43% screening coverage for women aged 35–44 years is still far off the WHO 2030 target of 70% screening coverage.

One exciting finding of this study is that traditional disadvantages borne by the rural areas may have begun to dissipate as suggested by multivariate logistic analysis. It again points to the positive impact of the national free screening program in rural areas over the past decade. As the national screening program became the National Basic Public Health Service Program in 2019, national and local policy as well as financial support for cervical cancer screening should be continued to maintain ongoing progress in rural screening uptake. Furthermore, among individual socioeconomic and health-related disparities in screening uptake, which corroborate with previous studies in China and abroad (9), regular health-checkups had strong positive effects over screening uptake, which highlights the importance of strengthened access to health services and health education beyond cancer screening. Moreover, this study suggests excessive screening uptake in the 20–24

age group especially in rural areas, which falls outside the recommended age groups of national screening recommendations (10). To meet the WHO 2030 target, health education and outreach efforts should be directed more toward the targeted age groups.

This study is limited by inaccuracies of self-reported data, potential unequal representation of screening program areas across the sampling regions, and the lack of survey questions on sociopsychological factors of screening uptake. Future studies using administrative data will offer a more definitive look into screening coverage. Qualitative studies on the drivers and barriers of screening uptake will also be helpful in improving screening program design. Moreover, this study only addresses screening coverage without touching upon screening quality control, which is crucial to the effectiveness of any screening program.

In conclusion, this study provides the latest estimate of cervical cancer screening coverage in China based on nationally and provincially representative survey data in 2018–2019. Approximately 43.4% of women aged 35–44 years and 36.8% of women aged 35–64 years reported having had cervical cancer screening in China in 2018–2019. To close the gaps with the WHO target for 2030, national and local policy and financial

support should be maintained for cervical cancer screening services, health education and outreach efforts should be focused on targeted age groups, and accessibility of health services should be strengthened in the rural areas and in central and western regions.

doi: 10.46234/ccdcw2022.217

Corresponding authors: Jing Wu, wujing@chinacdc.cn; Xiaoying Zheng, xzheng@pku.edu.cn; Linhong Wang, wanglinhong@ncncd.chinacdc.cn.

¹ Division of NCD and Risk Factor Surveillance, National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China; ² Institute of Population Research /APEC Health Science Academy (HeSAY), Peking University, Beijing, China; ³ National Center for Chronic and Noncommunicable Disease Control and Prevention, China CDC, Beijing, China; ⁴ Institute of Medical Information, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; ⁵ Yenching Academy, Peking University, Beijing, China; ⁶ Chinese Center for Disease Control and Prevention, Beijing, China.

* Joint first authors.

Submitted: October 27, 2022; Accepted: November 30, 2022

REFERENCES

- World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. 2020. <https://www.who.int/publications/i/item/9789240014107>. [2022-6-28].
- Zheng RS, Sun KX, Zhang SW, Zeng HM, Zou XN, Chen R, et al. Report of cancer epidemiology in China, 2015. *Chin J Oncol* 2019;41(1):19 – 28. <http://dx.doi.org/10.3760/cma.j.issn.0253-3766.2019.01.008>. (In Chinese).
- Chen WQ, Zheng RS, Zhang SW, Zeng HM, Xia CF, Zuo TT, et al. Cancer incidence and mortality in China, 2013. *Cancer Lett* 2017;401:63 – 71. <http://dx.doi.org/10.1016/j.canlet.2017.04.024>.
- National Health Commission. Working plan of cervical cancer screening. <http://www.nhc.gov.cn/fys/s3581/202201/cad44d88acca4ae49e12dab9176ae21c/files/7afa7269d02c4ba793b40561e8088c27.pdf>. [2022-1-18]. (In Chinese).
- Wang BH, He MF, Chao A, Engelgau MM, Saraiya M, Wang LM, et al. Cervical cancer screening among adult women in China, 2010. *Oncologist* 2015;20(6):627 – 34. <http://dx.doi.org/10.1634/theoncologist.2014-0303>.
- Bao HL, Wang LH, Wang LM, Fang LW, Zhang M, Zhao ZP, et al. Study on the coverage of cervical and breast cancer screening among women aged 35-69 years and related impact of socioeconomic factors in China, 2013. *Chin J Epidemiol* 2018;39(2):208 – 12. <http://dx.doi.org/10.3760/cma.j.issn.0254-6450.2018.02.014>. (In Chinese).
- Zhang M, Zhong YJ, Zhao ZP, Huang ZJ, Zhang X, Li C, et al. Cervical cancer screening rates among Chinese women — China, 2015. *China CDC Wkly* 2020;2(26):481 – 6. <http://dx.doi.org/10.46234/ccdcw2020.128>.
- Bruni L, Serrano B, Roura E, Alemany L, Cowan M, Herrero R, et al. Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis. *Lancet Glob Health* 2022;10(8):E1115 – 27. [http://dx.doi.org/10.1016/S2214-109X\(22\)00241-8](http://dx.doi.org/10.1016/S2214-109X(22)00241-8).
- Islam RM, Billah B, Hossain N, Oldroyd J. Barriers to cervical cancer and breast cancer screening uptake in low-income and middle-income countries: a systematic review. *Asian Pac J Cancer Prev* 2017;18(7):1751 – 63. <http://dx.doi.org/10.22034/APJCP.2017.18.7.1751>.
- Wang LH, Zhao GL. Expert panel interpretation: comprehensive prevention and control guidelines for cervical cancer in China. *Chin J Woman Child Health Res* 2018;29(1):1 – 3. <http://dx.doi.org/10.3969/j.issn.1673-5293.2018.01.001>. (In Chinese).

Preplanned Studies

Prevalence of High-Risk Human Papillomavirus in Cervical Intraepithelial Neoplasia in the Pre-Vaccine Era — China, 2017–2018

Heling Bao^{1,2,&}; Weihong Chen^{3,&}; Xiaosong Zhang⁴; Hui Bi⁴; Yun Zhao⁵; Liwen Fang²; Shu Cong²; Feng Tan^{3,#}; Linhong Wang^{2,#}

Summary

What is already known about this topic?

Human papillomavirus (HPV) type-specific strategies play a key role in the prevention of cervical intraepithelial neoplasia (CIN), but evidence on the HPV type-specific prevalence in CIN is limited.

What is added by this report?

This multicentric study estimates the prevalence of high-risk HPV types in CIN cases and the associations of HPV infection patterns with high-grade CIN in China in 2017–2018.

What are the implications for public health practice?

Population-based prevention strategies should give preference to HPV-16 and 18, and strategies for non-16/18 high-risk HPV are essential for the elimination of cervical cancer.

Persistent infection with high-risk human papillomavirus (HPV) leads to invasive cervical cancer (1–2). The World Health Organization calls for the elimination of cervical cancer through HPV vaccination, screening for progressive cervical intraepithelial neoplasia (CIN), and early treatment (3). Understanding the prevalence of high-risk HPV types in CIN cases can inform prevention strategies. Prevalence data, however, has not been updated in China since 2009 (4). This clinically multicentric study investigated the HPV prevalence in CIN cases in 2017–2018, which was prior to the introduction of HPV vaccines in the mainland of China. The results showed that more than 90% of CIN2/3 cases were in individuals positive for high-risk HPV. In particular, HPV-16/18 were significantly associated with an increased risk of high-grade lesions. This study provides evidence to inform HPV-based screening and vaccination strategies and suggests that HPV-16/18 prevention should be prioritized.

From March 2017 to October 2018, the study recruited women aged 20–64 years old who exhibited abnormalities during screenings or had genital tract symptoms. We selected eight tertiary hospitals or maternal and child healthcare hospitals from 7 provincial-level administrative divisions (PLADs) including Beijing, Shanxi, Shannxi, Jiangsu, Hunan, Guangdong, and Chongqing according to the geographic distribution and burden of cervical cancer in China. These hospitals were local centers for cervical prevention and treatment and were the designated hospitals for referred patients in a prior population-based screening (5). A clinician interviewed patients with a structured questionnaire and collected information on demographic characteristics, the history of screening and diseases, and genital symptoms. Then a cervical specimen was obtained by the clinician with a brush and stored in a reserve (Hologic, Bedford, MA, USA) for HPV testing and cytology examination. Cobas HPV assay (Cobas 4800, Roche Molecular Systems, Pleasanton, CA, USA) was used and reported for HPV-16, -18, and 12 other non-16/18 high-risk types (including HPV-31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, and -68). Liquid-based technology (ThinPrep, Hologic, MA, USA) was used to generate slides for cytology examination. A panel of cytotechnicians examined these slides under the microscope and reported the results according to the Bethesda terminology. A skilled cytologist selected all the positive slides and randomly selected 20% of negative slides to review the results.

Each patient underwent a colposcopy examination, colposcopy-directed four-quadrant biopsy, histological confirmation, and endocervical curettage. Two pathologists from local hospitals reviewed the pathological sections and reported the results according to the CIN terminology. Two skilled pathologists independently reviewed the results to avoid false-negative or false-positive results. This study included

cases with CIN grades 1, 2, and 3, and adenocarcinoma in situ (AIS). We classified AIS as CIN3 and defined CIN2/3 as high-grade lesions.

We estimated the overall and age-specific prevalence of high-risk HPV in all CIN cases and CIN2/3 cases, respectively. Fisher's exact method was used to estimate 95% confidence intervals (CI). To show the age-specific trends of HPV prevalence in CIN2/3, we used generalized additive models with quasibinomial distribution, adjusting for region and smoking status. Furthermore, we evaluated the association of different HPV infection patterns with high-grade CIN by multivariate ordinal or binomial logistic regression, adjusting for age, region, and smoking status. The former regarded the outcome as an ordinal variable, whereas the latter regarded CIN1 and CIN1/2 as reference groups, respectively. All analyses were done with SAS (version 9.4; SAS Institute, Cary, USA) and R software (version 3.5.3; R Foundation for Statistical Computing, Vienna, Austria).

There were 1,480 histologically confirmed CIN cases tested with HPV infection status, including 740 CIN1, 396 CIN2, and 344 CIN3 (Table 1). The median age was 37.6 years old for all CIN cases. The prevalence of 14 high-risk HPV types in all CIN cases was 85.1% (95% CI: 83.2%–86.9%). The prevalence of all HPV types and HPV-16/18 prevalence in CIN2/3 cases were 92.2% (95% CI: 90.0%–94.0%) and 52.0% (95% CI: 48.4%–55.7%), respectively, which is higher than in CIN1 cases (78.0%, 95% CI: 74.8%–80.9% and 25.4%, 95% CI: 22.3%–28.7%). In contrast, the prevalence of non-16/18 high-risk HPV types in CIN1 was 64.3%, 95% CI: 60.8%–67.8%), which was higher than in CIN2/3 (56.6%, 95% CI: 53.0%–60.2%). There were 50 cases with invalid cytology results. Among CIN2/3 cases with HPV positive results, 4.9% were classified as normal cytology, and these cases mostly occurred in those who were positive for non-16/18 HPV types.

The age-specific HPV-16/18 prevalence in CIN2/3 ranged from 49.4% to 65.9%, and non-16/18 HPV type prevalence ranged from 26.8% to 46.2% (Figure 1A). The highest HPV-16/18 prevalence was observed in individuals aged 20–29 years, whereas the highest prevalence of non-16/18 HPV types was observed in individuals aged 40–49 years. Overall, the non-linear models revealed HPV prevalence was equivalent across age groups for CIN2/3 (Figure 1B and 1C). Nonetheless, the association of HPV-16/18 with CIN2/3 was slightly more prevalent among younger (<30 years) and older (>50 years) women.




FIGURE 1. Age-specific HPV prevalence in cases with cervical intraepithelial neoplasia 2/3 and the association between HPV infection and age. (A) The prevalence of HPV-16/18 and non-16/18 high-risk HPV types in CIN2/3; (B) The non-linear association of age with HPV-16/18 positive in CIN2/3 cases; (C) The non-linear association of age with non-16/18 HPV types positive in CIN2/3 cases. Abbreviation: HPV=human papillomavirus; CIN=cervical intraepithelial neoplasia.

The pattern of HPV infection was associated with an increased risk of high-grade CIN to a different extent (Table 2). Ordinal multivariate analyses revealed that patients with HPV-16/18 and non-16/18 HPV types had increased odds of 5.5 ($OR=5.51$, 95% CI: 3.92–7.73) and 2.1 ($OR=2.14$, 95% CI: 1.54–2.99) of developing CIN2/3, respectively, compared to patients negative for HPV. Furthermore, HPV-16-related infection was associated with a 7-fold increased risk of developing CIN2/3 ($OR=6.96$, 95% CI: 4.92–9.84). These results remained stable in binomial multivariate analyses.

TABLE 1. Prevalence of HPV types in cases with cervical intraepithelial neoplasia grade 1, 2, and 3.

HPV types	All CIN (n=1,480)		CIN 1 (n=740)		CIN 2 (n=396)		CIN 3 (n=344)		CIN2/3 (n=740)		P for CIN2/3 vs. CIN1
	n	Prevalence (95% CI)	n	Prevalence (95% CI)	n	Prevalence (95% CI)	n	Prevalence (95% CI)	n	Prevalence (95% CI)	
All HPV+	1,259	85.1 (83.2–86.9)	577	78.0 (74.8–80.9)	358	90.4 (87.1–93.1)	324	94.2 (91.2–96.4)	682	92.2 (90.0–94.0)	<0.001
Normal	106	7.2 (5.9–8.6)	70	9.5 (7.5–11.6)	24	6.1 (3.9–8.9)	12	3.5 (1.6–5.4)	36	4.9 (3.4–6.7)	<0.001
ASC–US or worse	1,120	75.7 (73.5–77.9)	489	66.1 (62.5–69.5)	328	82.8 (78.8–86.4)	303	88.1 (84.2–91.3)	631	85.3 (82.5–87.8)	<0.001
HPV-16	496	33.5 (31.1–36.0)	137	18.5 (15.8–21.5)	165	41.7 (36.8–46.7)	194	56.4 (51.0–61.7)	359	48.5 (44.9–52.2)	<0.001
Normal	36	2.4 (1.7–3.4)	17	2.3 (1.3–3.7)	11	2.8 (1.4–4.9)	8	2.3 (1.0–4.5)	19	2.6 (1.6–4.0)	0.745
ASC–US or worse	452	30.5 (28.2–33.0)	119	16.1 (13.5–18.9)	152	38.4 (33.6–43.4)	181	52.6 (47.2–58.0)	333	45.0 (41.4–48.7)	<0.001
HPV-18	92	6.2 (5.0–7.6)	57	7.7 (5.9–9.9)	22	5.7 (3.5–8.3)	13	3.8 (2.0–6.4)	35	4.7 (3.3–6.5)	0.018
Normal	15	1.0 (0.5–1.5)	11	1.5 (0.7–2.6)	4	1.0 (0.3–2.6)	NA	NA	4	0.5 (0.2–1.4)	0.069
ASC–US or worse	71	4.8 (3.8–6.0)	42	5.7 (4.1–7.6)	17	4.3 (2.5–6.8)	12	3.5 (1.8–6.0)	29	3.9 (2.6–5.6)	0.114
Other HPV types	895	60.5 (57.9–63.0)	476	64.3 (60.8–67.8)	237	59.9 (54.8–64.7)	182	52.9 (47.5–58.3)	419	56.6 (53.0–60.2)	0.002
Normal	69	4.7 (3.7–5.9)	50	6.8 (5.1–8.8)	13	3.3 (1.8–5.6)	6	1.7 (0.6–3.8)	394	2.6 (1.6–4.0)	<0.001
ASC–US or worse	804	54.3 (51.8–56.9)	410	55.4 (51.7–59.0)	221	55.8 (50.8–60.8)	173	50.3 (44.9–55.7)	19	53.2 (49.7–56.8)	0.404
HPV-16/18	573	38.7 (36.2–41.3)	188	25.4 (22.3–28.7)	184	46.5 (41.5–51.5)	201	58.4 (53.0–63.7)	385	52.0 (48.4–55.7)	<0.001
Normal	49	3.3 (2.5–4.4)	26	3.5 (2.3–5.1)	15	3.8 (2.1–6.2)	8	2.3 (1.0–4.5)	23	3.1 (2.0–4.6)	0.663
ASC–US or worse	510	34.5 (32.0–36.9)	157	21.2 (18.3–24.3)	166	41.9 (37.0–47.0)	187	54.4 (48.9–59.7)	353	47.7 (44.1–51.3)	<0.001
Other HPV types (no 16/18)	686	46.4 (43.8–49.0)	389	52.6 (48.9–56.2)	174	43.9 (39.0–49.0)	123	35.8 (30.7–41.1)	297	40.1 (36.6–43.7)	<0.001
Normal	57	3.9 (2.9–5.0)	44	6.0 (4.2–7.7)	9	2.3 (1.0–4.3)	4	1.2 (0.1–2.3)	13	1.8 (0.9–3.0)	<0.001
ASC–US or worse	610	41.2 (38.7–43.8)	332	44.9 (41.3–48.5)	162	40.9 (36.0–45.9)	116	33.7 (28.7–38.7)	278	37.6 (34.1–41.2)	0.004
HPV-18 related (no 16)	77	5.2 (4.1–6.3)	51	6.9 (5.2–9.0)	19	4.8 (2.9–7.4)	7	2.0 (0.8–4.2)	26	3.5 (2.3–5.1)	0.003
Normal	13	0.9 (0.4–1.4)	9	1.2 (0.6–2.3)	4	1.0 (0.1–2.0)	NA	NA	4	0.5 (0.2–1.4)	0.164
ASC–US or worse	58	3.9 (3.0–5.0)	38	5.1 (3.7–7.0)	14	3.5 (1.7–5.4)	6	1.7 (0.4–3.1)	20	2.7 (1.5–3.9)	0.016

Abbreviation: CIN=cervical intraepithelial neoplasia; HPV=human papillomavirus; CI=confidence interval; ASC–US=atypical squamous cells of undetermined significance; NA=not available.

TABLE 2. Association of HPV infection pattern with high-grade cervical intraepithelial neoplasia in cases.

Model	Dependent variable	Ordinal logistic regression for CIN 1, 2, and 3		Binomial logistic regression for CIN2/3 vs. CIN1		Binomial logistic regression for CIN3 vs. CIN1/2	
		OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
Model 1	HPV negative	Reference		Reference		Reference	
	Other HPV types (no HPV-16/18)	2.14 (1.54–2.99)	<0.001	2.15 (1.54–3.02)	<0.001	2.12 (1.28–3.50)	0.003
	HPV-16/18	5.51 (3.92–7.73)	<0.001	5.74 (4.04–8.15)	<0.001	5.07 (3.09–8.32)	<0.001
Model 2	HPV negative	Reference		Reference		Reference	
	Other HPV types (no HPV-16/18)	2.17 (1.55–3.02)	<0.001	2.17 (1.54–3.03)	<0.001	2.13 (1.29–3.52)	0.003
	HPV-16 related	6.96 (4.92–9.84)	<0.001	7.48 (5.19–10.76)	<0.001	6.12 (3.71–10.08)	<0.001
	HPV-18 related (no HPV-16)	1.33 (0.76–2.31)	0.305	1.40 (0.80–2.46)	0.296	0.92 (0.37–2.29)	0.864

Abbreviation: CIN=cervical intraepithelial neoplasia; HPV=human papillomavirus; OR=odds ratio; CI=confidence interval.

DISCUSSION

This 2017–2018 study obtained histological confirmations from almost 1,500 CIN cases and is therefore the largest study in China to report the prevalence of HPV types in CIN cases in the country's pre-vaccine era. We estimated that more than 90% of CIN2/3 patients were positive for high-risk HPV, suggesting that HPV-focused strategies may be important for the prevention of cervical cancer. Furthermore, our results showed that HPV-16 and HPV-18 were significantly associated with an increased risk of high-grade lesions and that preventing these subtypes should be prioritized when designing cervical cancer vaccination and screening strategies.

Consistent with previous research, this study showed a high HPV prevalence (92%) in CIN and an association between high-risk HPV types and CIN2/3. These findings emphasize the importance of HPV-based screening and vaccination strategies to eliminate and mitigate cervical cancer in China. In this study, the HPV prevalence in CIN2/3 was slightly lower than in the previous multicentric study of China in 2009 (94.2% vs. 98.9%) (4). Both studies tested all high-risk HPV types and indicated the importance of HPV-based strategies for prevention of CIN. However, HPV-16 prevalence decreased by approximately 30% in CIN2/3 patients in our more recent study (48.5% vs. 68.7%). Given that HPV vaccination has not been implemented in the population, the reduction may be related to screening and subsequent treatment, which would protect against subsequent HPV infection by antigen-presenting effects (6). Our results showed a low prevalence of HPV-18 in CIN2/3 patients and an OR without significance. This could be explained by a smaller number of AIS cases in the study.

Adenocarcinoma accounted for a small proportion of cervical cancer but was closely related to HPV-18 infection (7–8).

The proportion of non-16/18 high-risk HPV types in CIN2/3 was higher than in the study in 2009 (4). Although these non-16/18 HPV types have a lower risk of CIN2/3 than HPV-16/18, they are predominant in Chinese women, particularly HPV-52 and -58 (9). After the application of bivalent vaccines and screening based on HPV-16/18, these HPV types would gradually change to the predominant types. Among the CIN2/3 cases with non-16/18 HPV type positives, 1.8% were classified as normal cytology CIN2/3 and would be missed in the screening. Thus, primary HPV screening with HPV-16/18 genotyping was feasible but new stratification technology should be developed to reduce underdiagnosis.

The bimodal pattern of HPV prevalence in the population was identified by many studies in China (9–10). Nonetheless, our age-specific analyses showed that the roles of different HPV types were equivalent across the age spectrum. Furthermore, these results indicate that HPV vaccinations before the age of 20 should provide benefits that last until patients are 60 years old.

The key limitation was that results for HPV infection were from cervical scraping rather than paraffin-embedded biopsy specimens, which could lead to misclassification bias or false-negative results. A small spectrum of 14 HPV types also increased the likelihood of false negatives. Nonetheless, a high-sensitive PCR-based assay would reduce the risk of misclassification, and the proportion of HPV-negative CIN2+ in our study was similar to previous studies (11–12).

In conclusion, HPV-based screening and HPV

vaccination strategies greatly influence the prevention of cervical cancer in China. HPV-16 and HPV-18 should be priority vaccinations in China, and the prevention of non-16/18 high-risk HPV types will be essential to eliminate cervical cancer in the future.

Acknowledgement: All research staff from the hospitals and health centers associated with this project.

Conflicts of interest: No conflicts of interest.

Funding: Chinese Association of Maternal and Child Health Studies (2017AMCHS006) and National Natural Science Foundation of China (81903328).

doi: 10.46234/ccdcw2022.218

Corresponding authors: Feng Tan, tanfeng@chinacdc.cn; Linhong Wang, linhong@chinawch.org.cn.

¹ Institute of Medical Information, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; ² National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China; ³ Chinese Center for Disease Control and Prevention, Beijing, China; ⁴ Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing, China; ⁵ Department of Obstetrics and gynecology, Peking University People's Hospital, Beijing, China.
 & Joint first authors.

Submitted: October 26, 2022; Accepted: November 29, 2022

REFERENCES

- Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. *Lancet* 2013;382(9895):889 – 99. [http://dx.doi.org/10.1016/S0140-6736\(13\)60022-7](http://dx.doi.org/10.1016/S0140-6736(13)60022-7).
- de Sanjose S, Quint WGV, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. *Lancet Oncol* 2010;11(11):1048 – 56. [http://dx.doi.org/10.1016/S1470-2045\(10\)70230-8](http://dx.doi.org/10.1016/S1470-2045(10)70230-8).
- Brisson M, Drolet M. Global elimination of cervical cancer as a public health problem. *Lancet Oncol* 2019;20(3):319 – 21. [http://dx.doi.org/10.1016/S1470-2045\(19\)30072-5](http://dx.doi.org/10.1016/S1470-2045(19)30072-5).
- Chen W, Zhang X, Molijn A, Jenkins D, Shi JF, Quint W, et al. Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18. *Cancer Causes Control* 2009;20(9):1705 – 13. <http://dx.doi.org/10.1007/s10552-009-9422-z>.
- Bao HL, Bi H, Zhang XS, Zhao Y, Dong Y, Luo XP, et al. Artificial intelligence-assisted cytology for detection of cervical intraepithelial neoplasia or invasive cancer: a multicenter, clinical-based, observational study. *Gynecol Oncol* 2020;159(1):171 – 8. <http://dx.doi.org/10.1016/j.ygyno.2020.07.099>.
- Passmore JAS, Morroni C, Shapiro S, Williamson AL, Hoffman M. Papanicolaou smears and cervical inflammatory cytokine responses. *J Inflamm* 2007;4:8. <http://dx.doi.org/10.1186/1476-9255-4-8>.
- Ronco G, Franceschi S, Segnan N. HPV16 and HPV18 genotyping in cervical cancer screening. *Lancet Oncol* 2011;12(9):831 – 2. [http://dx.doi.org/10.1016/S1470-2045\(11\)70195-4](http://dx.doi.org/10.1016/S1470-2045(11)70195-4).
- Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. *Lancet Glob Health* 2020;8(2):e191 – 203. [http://dx.doi.org/10.1016/S2214-109X\(19\)30482-6](http://dx.doi.org/10.1016/S2214-109X(19)30482-6).
- Bao HL, Jin C, Wang S, Song Y, Xu ZY, Yan XJ, et al. Prevalence of cervicovaginal human papillomavirus infection and genotypes in the pre-vaccine era in China: a nationwide population-based study. *J Infect* 2021;82(4):75 – 83. <http://dx.doi.org/10.1016/j.jinf.2021.02.017>.
- Zhao FH, Lewkowitz AK, Hu SY, Chen F, Li LY, Zhang QM, et al. Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies. *Int J Cancer* 2012;131(12):2929 – 38. <http://dx.doi.org/10.1002/ijc.27571>.
- Petry KU, Cox JT, Johnson K, Quint W, Ridder R, Sideri M, et al. Evaluating HPV-negative CIN2+ in the ATHENA trial. *Int J Cancer* 2016;138(12):2932 – 9. <http://dx.doi.org/10.1002/ijc.30032>.
- Reich O, Regauer S, Kashofer K. Possibly carcinogenic HPV subtypes are a cause of HSIL and negative clinical HPV tests - A European prospective single center study. *Gynecol Oncol* 2020;158(1):112 – 6. <http://dx.doi.org/10.1016/j.ygyno.2020.04.685>.

Preplanned Studies

Prevalence of High-Risk Human Papillomavirus by Subtypes Among Rural Women Aged 35–64 Years — Guangzhou City, Guangdong Province, China, 2019–2021

Dantong Shao^{1,2,3,&}; Xiaoyan Xia^{1,2,4,&}; Huihui Liu^{1,2,4}; Mingxi Huang^{1,3,5}; Jia Yu^{2,4}; Jianrong He^{1,3,5,#}; Xiu Qiu^{1,2,5,#}

Summary

What is already known about this topic?

Little is known about the infection pattern for high-risk human papillomavirus (hrHPV) subtypes in rural areas in southern China.

What is added by this report?

The prevalence of HPV-16, 18, and the other 12 hrHPV subtypes were 0.71%, 0.34%, and 4.50%, respectively, among rural women in Guangzhou. The prevalence of HPV-16 and the other 12 hrHPV subtypes increased with age, but there was no evident age trend for HPV-18 prevalence.

What are the implications for public health practice?

Epidemiological characteristics of hrHPV prevalence in rural Guangzhou should be considered to identify high-risk populations of hrHPV infection and determine follow-up strategies.

Cervical cancer, the fourth most common cancer and the fourth leading cause of cancer death in women worldwide (1), is preventable through effective screening and vaccination. Human papillomavirus (HPV) testing is now recommended as the primary method in cervical cancer screening (2). HPV-16 and 18 are the most carcinogenic high-risk (hrHPV) subtypes and account for approximately 70% of cervical cancers (3). Understanding the prevalence patterns of different hrHPV subtypes is important to identify target populations for screening and vaccination. However, the age-specific prevalence of different hrHPV subtypes remains unclear among women in rural areas in southern China. A total of 159,251 women aged 35–64 years who participated in a cervical cancer screening program in rural areas in Guangzhou City, Guangdong Province, China, from 2019–2021 were included in this population-based study. All women received the hrHPV test using Roche Cobas 4800 (Roche Molecular Systems, Pleasanton,

USA). We found that the prevalences of HPV-16, 18, and the other 12 hrHPV types were 0.71%, 0.34%, and 4.50%, respectively, among rural women in Guangzhou. We observed the prevalence of HPV-16 declined in the age group of 35–49 years and increased by age group afterwards, whereas the prevalence of the other 12 hrHPV subtypes increased with age from 40–44 years old ($P_{\text{trend}} < 0.01$), but there was no evident trend for HPV-18 prevalence across the age groups ($P_{\text{trend}} = 0.70$). Our findings might have implications in the identification and follow-up for high-risk population of hrHPV infection.

This study was based on a population-based cervical cancer screening program covering all seven rural administrative districts in Guangzhou during 2019–2021. All screened women aged 35–64 years with rural registered permanent residence in Guangzhou were included in the study. All women received a gynecological examination and the hrHPV test using Roche Cobas 4800 (Roche Molecular Systems, Pleasanton, USA) HPV Detection (Cobas). Cobas could specifically identify HPV-16 and HPV-18 while concurrently detecting the other 12 hrHPV types (HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68). All women provided written informed consent before screening. Age-specific prevalence of hrHPV infection was calculated by five-year age groups. The Cochran-Armitage test was used to examine the overall linear trends of the prevalence of hrHPV subtypes across age groups. The two-sided Poisson test was used to compare the prevalence ratios (PR) across age-groups and calculate the 95% confidence interval (CI). Stratified analyses of prevalence of hrHPV subtypes were performed among women who were first time to participate in HPV screening or not. Analyses were performed using SAS (version 9.4; SAS Institute Inc., Cary, NC, USA) or R (version 4.0.3; R Core Team, Vienna, Austria).

A total of 159,251 women aged 35–64 years (mean: 46.51 years) were included in the study. Women aged

35–39 years old accounted for 23.18% of the participants while 5.04% of women were 60–64 years old. Of the included participants, 8,465 (5.32%) women were detected as hrHPV positive, with 1,130 (0.71%) positive for HPV-16, 538 (0.34%) positive for HPV-18 and 7,168 (4.50%) positive for the other 12 hrHPV types (Table 1). Among women who tested as hrHPV positive, 13.35% were positive for HPV-16, 6.36% for HPV-18, and 84.68% for the other 12 hrHPV subtypes.

Age-specific prevalence for hrHPV subtypes is shown in Table 2. The prevalence of HPV-16 slightly declined from 35–49 years group and increased with age afterwards, indicating an overall upward trend ($Z=-3.19$, $P_{\text{trend}}<0.01$, Figure 1). Highest prevalence

of HPV-16 was observed among women of 60–64 years, with a PR of 1.34 (95% CI: 1.02–1.73) compared with those of 35–39 years (Table 2). Women at 60–64 years also had the highest prevalence of HPV-18, but there was no evident trend for HPV-18 prevalence across the age groups ($Z=-0.39$, $P_{\text{trend}}=0.70$). The other 12 hrHPV subtypes also had an increasing prevalence along with age ($Z=-6.16$, $P_{\text{trend}}<0.01$), with the highest prevalence observed among women at 60–64 years (PR, 1.39; 95% CI: 1.26–1.54). Stratified analysis showed similar age-specific prevalence patterns between women undergoing HPV screening for the first time and those who had participated before (Supplementary Figure S1, available in <http://weekly.chinacdc.cn>).

TABLE 1. The prevalence of hrHPV subtypes in rural Guangzhou, China, 2019–2021.

Infection patterns	No. of positive	Prevalence (%) (95% CI)	Proportion of hrHPV (%)
Any types of infection			
Any hrHPV subtypes	8,465	5.32 (5.21–5.43)	100.00
Any HPV-16	1,130	0.71 (0.67–0.75)	13.35
Any HPV-18	538	0.34 (0.31–0.37)	6.36
Any pooled 12 hrHPV types	7,168	4.50 (4.40–4.60)	84.68
HPV-16 or HPV-18	1,651	1.04 (0.99–1.09)	19.50
Co-infection			
HPV-16 + Other hrHPV types*	249	0.16 (0.14–0.18)	2.94
HPV-18 + Other hrHPV types†	134	0.08 (0.07–0.10)	1.58
HPV-16 + 18	12	0.008 (0.004–0.014)	0.14
HPV-16 +18 + Pooled 12 hrHPV types	5	0.003 (0.001–0.007)	0.06

Abbreviation: hrHPV=high-risk human papillomavirus, CI=confidence interval.

* Other hrHPV types means pooled 12 hrHPV types or HPV-18.

† Other hrHPV types means pooled 12 hrHPV types or HPV-16.

TABLE 2. The prevalence of HPV-16, HPV-18, and the other 12 hrHPV subtypes by age group during 2019–2021 in rural Guangzhou, China (N=159,251).

Age group	Total participants (%)	No. of positive	HPV-16		No. of positive	HPV-18		Pooled 12 hrHPV		
			Positive rate (%) (95% CI)	Prevalence ratio (95% CI)		Positive rate (%) (95% CI)	Prevalence ratio (95% CI)	No. of positive	Positive rate (%) (95% CI)	Prevalence ratio (95% CI)
35–39	36,914 (23.18)	262	0.71 (0.63–0.80)	1.00	136	0.37 (0.31–0.44)	1.00	1,623	4.40 (4.19–4.61)	1.00
40–44	29,917 (18.78)	190	0.64 (0.55–0.73)	0.89 (0.74–1.08)	93	0.31 (0.25–0.38)	0.84 (0.64–1.11)	1,243	4.15 (3.93–4.39)	0.94 (0.88–1.02)
45–49	34,974 (21.96)	206	0.59 (0.51–0.68)	0.83 (0.69–1.00)	104	0.30 (0.24–0.36)	0.81 (0.62–1.05)	1,511	4.32 (4.11–4.54)	0.98 (0.92–1.05)
50–54	31,151 (19.56)	232	0.75 (0.65–0.85)	1.05 (0.88–1.26)	112	0.36 (0.30–0.43)	0.98 (0.75–1.26)	1,364	4.38 (4.16–4.61)	1.00 (0.93–1.07)
55–59	18,275 (11.48)	164	0.90 (0.77–1.05)	1.26 (1.03–1.54)	53	0.29 (0.22–0.38)	0.79 (0.56–1.09)	936	5.12 (4.81–5.45)	1.16 (1.07–1.26)
60–64	8,020 (5.04)	76	0.95 (0.75–1.19)	1.34 (1.02–1.73)	40	0.50 (0.36–0.69)	1.35 (0.93–1.94)	491	6.12 (5.61–6.67)	1.39 (1.26–1.54)
Total	159,251	1,130	0.71 (0.67–0.75)	–	538	0.34 (0.31–0.37)	–	7,168	4.50 (4.40–4.60)	–

Abbreviation: hrHPV=high-risk human papillomavirus; CI=confidence interval.

“–” means not applicable.




FIGURE 1. The prevalence and trend of hrHPV subtypes by age group during 2019–2021 in rural Guangzhou, China ($N=159,251$).

Abbreviation: hrHPV=high-risk human papillomavirus.

DISCUSSION

In this study, we characterized the prevalence pattern of hrHPV subtypes among rural women in Guangzhou, China. We found the prevalences of HPV-16, HPV-18, and the other 12 hrHPV subtypes were 0.71%, 0.34%, and 4.50%, respectively. An overall upward trend in prevalence was observed for both HPV-16 and the other 12 hrHPV across age groups. Although there was no significant age trend for HPV-18, women at 60–64 years appeared to have the highest prevalence of HPV-18.

It has been well documented that HPV-16 and HPV-18 have a higher likelihood of persistence and progression to cervical lesions compared with other oncogenic types, accounting for approximately 70% of cervical cancers globally (3). Understanding the prevalence of hrHPV subtypes is beneficial for decision making for both screening strategies and vaccination. The distribution of HPV-16 and HPV-18 in general population varies across continents: 5.8% and 2.3% in northern America, 4.8% and 0.9% in Europe, and 2.5% and 1.4% in Asia (mostly from India) (4). Even within China, the prevalence of hrHPV subtypes varies among different regions. For example, the prevalence of HPV-16 ranges from 0.71% in Guangdong Province to 3.62% in Zhejiang Province, whereas the prevalence of HPV-18 ranges from 0.28% in Jiangxi

Province to 1.48% in Zhejiang Province (5–7). These differences in hrHPV prevalence across regions could be due to different HPV testing approaches or different age structure of the population under investigation and might reflect actual geographic variations in hrHPV prevalence. Using the same method (i.e., Cobas) for a close age-distributed population (older than 30 years old) as this study, Guo revealed rates of 0.71% and 0.30% for HPV-16 and HPV-18 among a small sample ($n=986$) in Guangdong Province (6), while another study in Hubei Province ($n=313,704$) found that the prevalences of HPV-16 and HPV-18 were 1.51% and 0.46%, respectively (8).

This study found that different hrHPV subtypes presented different patterns for age distribution. It has been reported that the prevalence of HPV-16/18 gradually increased among 35–50 age group in general population in Guangdong Province, China (7). However, the prevalence of HPV-16 decreased to the lowest point in the 45–49 age group and then went upward in the current study. As for the prevalence of the other 12 hrHPV subtypes, a significant increase across age groups was observed in the rural women of Guangzhou. Another study also found a similar trend for HPV-52 and HPV-58 in Guangdong Province, China, which are the most common types in the other 12 hrHPV subtypes (7).

The findings of this study might have important implications in public health. First, the variability in prevalence patterns for different hrHPV subtypes across age groups indicates that women at different ages might have different risk factors for hrHPV infection. It provides a better understanding for the epidemiological characteristics of hrHPV in rural Guangzhou. Second, we found that women at an older age have a higher prevalence of HPV-16 and the other 12 hrHPV subtypes than those at a younger age. This suggests that elderly women deserve additional concern because most national guidelines recommend stopping cervical cancer screening at age 65 (9). Whether the high prevalence of hrHPV subtypes also translates into a higher cervical intraepithelial neoplasia burden in elderly women needs further investigation.

Although this study had the advantage of a large sample size, limitations remain. First, we are unable to identify the prevalence of each of the other 12 hrHPV because Cobas detects them concurrently. Second, pathological data were not available; thus, the association between HPV subtypes and cervical cancer or precancerous lesions could not be examined. Furthermore, only data from Guangzhou were

included in this study, it cannot be extrapolated to the whole rural area of China. Multiarea data are needed to characterize the prevalence of hrHPV subtypes in rural China.

In conclusion, we found that different hrHPV subtypes had different age-specific prevalence patterns and women at an older age had significantly higher prevalence of HPV-16 and the other 12 hrHPV subtypes. This information is helpful for better understanding the epidemiological characteristics of hrHPV subtypes in rural Guangzhou and provides a scientific basis for identification and follow-up of high-risk populations. Further investigations are warranted to investigate the prevalence and health effects of HPV-16 and the other 12 hrHPV subtypes in elderly women.

Acknowledgments: We thank Professor Gendie Lash for editing English language on our paper.

Funding: National Natural Science Foundation of China (82173525); Guangdong Science and Technology Department (2019B030301004, 2019B030316014, 2020B1111170001); Natural Science Foundation of Guangdong Province (2021A1515110194).

doi: 10.46234/ccdcw2022.219

Corresponding authors: Jianrong He, jianrong.he@bigcs.org; Xiu Qiu, xiu.qiu@bigcs.org.

¹ Division of Birth Cohort Study, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong Province, China; ² Department of Women's Health, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong Province, China; ³ Guangdong Provincial Key Laboratory of Research in Structural Birth Defect Disease, Guangzhou, Guangdong Province, China; ⁴ Guangdong Provincial Key Clinical Specialty of Woman and Child Health, Guangzhou, Guangdong Province, China; ⁵ Guangdong Provincial Clinical Research Center for Child Health, Guangzhou,


Guangdong Province, China.

* Joint first authors.

Submitted: October 28, 2022; Accepted: November 28, 2022

REFERENCES

- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2021;71(3):209 – 49. <http://dx.doi.org/10.3322/caac.21660>.
- Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. *Lancet Oncol* 2010;11(3):249 – 57. [http://dx.doi.org/10.1016/S1470-2045\(09\)70360-2](http://dx.doi.org/10.1016/S1470-2045(09)70360-2).
- World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations. *Vaccine* 2017;35(43): 5753 – 5. <http://dx.doi.org/10.1016/j.vaccine.2017.05.069>.
- Bruni L, Diaz M, Castellsagué M, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. *J Infect Dis* 2010;202(12):1789 – 99. <http://dx.doi.org/10.1086/657321>.
- Chen X, Xu HO, Xu WW, Zeng WJ, Liu JW, Wu Q, et al. Prevalence and genotype distribution of human papillomavirus in 961,029 screening tests in southeastern China (Zhejiang Province) between 2011 and 2015. *Sci Rep* 2017;7(1):14813. <http://dx.doi.org/10.1038/s41598-017-13299-y>.
- Guo CL, Du H, Belinson JL, Wang C, Huang X, Qu XF, et al. The prevalence and distribution of human papillomavirus among 10,867 Chinese Han women. *Infect Agent Cancer* 2021;16(1):21. <http://dx.doi.org/10.1186/s13027-021-00360-9>.
- Jing LP, Zhong XM, Zhong ZY, Huang WH, Liu Y, Yang G, et al. Prevalence of human papillomavirus infection in Guangdong Province, China: a population-based survey of 78,355 women. *Sex Transm Dis* 2014;41(12):732 – 8. <http://dx.doi.org/10.1097/OLQ.0000000000000201>.
- Wu P, Xiong HG, Yang M, Li L, Wu P, Lazare C, et al. Co-infections of HPV16/18 with other high-risk HPV types and the risk of cervical carcinogenesis: a large population-based study. *Gynecol Oncol* 2019;155(3):436 – 43. <http://dx.doi.org/10.1016/j.ygyno.2019.10.003>.
- Ren WH, Zhao XL, Zhao FH. Global guidelines for cervical cancer screening: a systematic review. *Natl Med J China* 2021;101:1882 – 9. <http://dx.doi.org/10.3760/cma.j.cn112137-20210115-00134>. (In Chinese).



SUPPLEMENTARY FIGURE S1. The prevalence and trend of hrHPV subtypes by age group in rural Guangzhou, China. (A) For women who participated in HPV screening for the first time (N=84,486); (B) For women who had previously participated in HPV screening (N=74,765).
 Abbreviation: hrHPV=high-risk human papillomavirus.

Indexed by PubMed Central (PMC), Emerging Sources Citation Index (ESCI), Scopus, Chinese Scientific and Technical Papers and Citations, and Chinese Science Citation Database (CSCD)

Copyright © 2022 by Chinese Center for Disease Control and Prevention

All Rights Reserved. No part of the publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of *CCDC Weekly*. Authors are required to grant *CCDC Weekly* an exclusive license to publish.

All material in *CCDC Weekly Series* is in the public domain and may be used and reprinted without permission; citation to source, however, is appreciated.

References to non-China-CDC sites on the Internet are provided as a service to *CCDC Weekly* readers and do not constitute or imply endorsement of these organizations or their programs by China CDC or National Health Commission of the People's Republic of China. China CDC is not responsible for the content of non-China-CDC sites.

The inauguration of *China CDC Weekly* is in part supported by Project for Enhancing International Impact of China STM Journals Category D (PIIJ2-D-04-(2018)) of China Association for Science and Technology (CAST).



Vol. 4 No. 48 Dec. 2, 2022

Responsible Authority

National Health Commission of the People's Republic of China

Sponsor

Chinese Center for Disease Control and Prevention

Editing and Publishing

China CDC Weekly Editorial Office
No.155 Changbai Road, Changping District, Beijing, China
Tel: 86-10-63150501, 63150701
Email: weekly@chinacdc.cn

CSSN

ISSN 2096-7071
CN 10-1629/R1